celz_10q.htm

0001477932-23-005935.txt : 20230811 0001477932-23-005935.hdr.sgml : 20230811 20230811164538 ACCESSION NUMBER: 0001477932-23-005935 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230811 DATE AS OF CHANGE: 20230811 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-41120 FILM NUMBER: 231164819 BUSINESS ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 BUSINESS PHONE: 480-399-2822 MAIL ADDRESS: STREET 1: 211 E. OSBORN RD. CITY: PHOENIX STATE: AZ ZIP: 85012 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 10-Q 1 celz_10q.htm FORM 10-Q celz_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2023

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to __________

Commission File Number: 000-53500

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

(Exact name of Registrant as specified in its charter)

Nevada

87-0622284

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

211 E Osborn Road, Phoenix, AZ		85012
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (480) 399-2822

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CELZ		The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated Filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒

As of August 11, 2023, there were 1,430,530 shares of the registrant’s common stock outstanding.

		Page Number
PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements

	Unaudited Condensed Consolidated Balance Sheets	3

	Unaudited Condensed Consolidated Statements of Operations	4

	Unaudited Condensed Consolidated Statements of Cash Flows	5

	Unaudited Condensed Consolidated Statements of Stockholder’ Equity (Deficit)	6

	Notes to Unaudited Condensed Consolidated Financial Statements	7

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	19

Item 4.	Controls and Procedures	19

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings	20

Item 6.	Exhibits	20

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS
	June 30, 2023			December 31, 2022
ASSETS
CURRENT ASSETS
Cash	$	3,989,550		$	8,320,519
Certificates of deposit		9,581,207			10,078,617
Inventory		10,194			10,194
Prepaids and other current assets		153,692			338,120
Total Current Assets		13,734,643			18,747,450

OTHER ASSETS
Other assets		3,281			3,281
Licenses, net of amortization		389,553			435,595
TOTAL ASSETS	$	14,127,477		$	19,186,326

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
Accounts payable	$	344,413		$	3,267,538
Accrued expenses		39,920			39,920
Advances from related party		14,194			14,194
Total Current Liabilities		398,527			3,321,652

TOTAL LIABILITIES		398,527			3,321,652

Commitments and contingencies

STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,127 and 1,407,625 issued and 1,431,126 and 1,407,624 outstanding at June 30, 2023 and December 31, 2022, respectively		1,431			1,408
Additional paid-in capital		69,693,425			69,675,124
Accumulated deficit		(55,965,906	)		(53,811,858	)
TOTAL STOCKHOLDERS' EQUITY		13,728,950			15,864,674
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
	$	14,127,477		$	19,186,326

The Accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	For the Three Months Ended June 30, 2023			For the Three Months Ended June 30, 2022			For the Six Months Ended June 30, 2023			For the Six Months Ended June 30, 2022

Revenues	$	-		$	-		$	-		$	15,000

Cost of revenues		-			-			-			6,791

Gross profit		-			-			-			8,209

OPERATING EXPENSES
Research and development		309,480			659,695			628,509			669,695
Selling, general and administrative		859,537			1,108,428			1,630,557			2,238,485
Amortization of patent costs		23,021			23,021			46,042			46,042
TOTAL EXPENSES		1,192,038			1,791,144			2,305,108			2,954,222

Operating loss		(1,192,038	)		(1,791,144	)		(2,305,108	)		(2,946,013	)

OTHER INCOME/(EXPENSE)
Interest income		89,913			-			151,060			-
Total other income (expense)		89,913			-			151,060			-

LOSS BEFORE PROVISION FOR INCOME TAXES		(1,102,125	)		(1,791,144	)		(2,154,048	)		(2,946,013	)

Provision for income taxes		-			-			-			-

NET LOSS	$	(1,102,125	)	$	(1,791,144	)	$	(2,154,048	)	$	(2,946,013	)

NET LOSS PER SHARE - BASIC AND DILUTED	$	(0.78	)	$	(1.99	)	$	(1.53	)	$	(3.81	)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED		1,409,948			901,125			1,408,793			773,970

The Accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

	For the Six Months Ended June 30, 2023			For the Six Months Ended June 30, 2022

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2,154,048	)	$	(2,946,013	)
Adjustments to reconcile net loss to
net cash used in operating activities:
Stock-based compensation		18,324			50,422
Amortization		46,042			46,042
Changes in assets and liabilities:
Accounts receivable		-			2,485
Inventory		-			(9,759	)
Prepaids and other current assets		184,428			(64,960	)
Accounts payable		(2,923,125	)		(451,181	)
Accrued expenses		-			40,535
Net cash used in operating activities		(4,828,379	)		(3,332,429	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Investments in certificates of deposit		(4,551,049	)		-
Redemptions of certificates of deposit		5,048,459			-
Net cash provided by investing activities		497,410			-

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock and warrants, net of issuance costs		-			15,471,775
Proceeds from exercise of warrants		-			445
Net cash provided by financing activities		-			15,472,220

NET INCREASE (DECREASE) IN CASH		(4,330,969	)		12,139,791
BEGINNING CASH BALANCE		8,320,519			10,723,870
ENDING CASH BALANCE	$	3,989,550		$	22,863,661

SUPPLEMENTAL CASH FLOW INFORMATION:
Cash payments for interest	$	-		$	9,186
Cash payments for income taxes	$	-		$	-

NON-CASH INVESTING AND FINANCING ACTIVITIES:
Conversion of management fees and patent liability into common stock	$	-		$	250,000

The Accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
December 31, 2022		-	$	-		-	$	-		-	$	-		1,407,624	$	1,408	$	69,675,124		$	(53,811,858	)	$	15,864,674

Round-up shares issued in reverse stock split		-		-		-		-		-		-		23,502		23		(23	)		-			-
Stock-based compensation		-		-		-		-		-		-		-		-		18,324			-			18,324
Net loss		-		-		-		-		-		-		-		-		-			(2,154,048	)		(2,154,048	)

June 30, 2023		-	$	-		-	$	-		-	$	-		1,431,126	$	1,431	$	69,693,425		$	(55,965,906	)	$	13,728,950

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in			Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital			Deficit			Equity
March 31, 2023		-	$	-		-	$	-		-	$	-		1,407,624	$	1,408	$	69,684,286		$	(54,863,781	)	$	14,821,913

Round-up shares issued in reverse stock split		-		-		-		-		-		-		23,502		23		(23	)		-			-
Stock-based compensation		-		-		-		-		-		-		-		-		9,162			-			9,162
Net loss		-		-		-		-		-		-		-		-		-			(1,102,125	)		(1,102,125	)

June 30, 2023		-	$	-		-	$	-		-	$	-		1,431,126	$	1,431	$	69,693,425		$	(55,965,906	)	$	13,728,950

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity
December 31, 2021		-	$	-		-	$	-		-	$	-		633,886	$	634	$	53,884,920	$	(43,667,814	)	$	10,217,740

Issuance of common stock and accompanying warrants, net of issuance costs		-		-		-		-		-		-		299,167		299		15,471,476		-			15,471,775
Common stock issued for related party patent liabilities		-		-		-		-		-		-		18,182		18		249,982		-			250,000
Common stock issued for warrant exercise		-		-		-		-		-		-		444,389		444		1		-			445
Stock-based compensation		-		-		-		-		-		-		-		-		50,422		-			50,422
Net loss		-		-		-		-		-		-		-		-		-		(2,946,013	)		(2,946,013	)

June 30, 2022		-	$	-		-	$	-		-	$	-		1,395,624	$	1,395	$	69,656,801	$	(46,613,827	)	$	23,044,369

	Series A Preferred Stock				Series B Preferred Stock				Series C Preferred Stock				Common Stock				Additional Paid-in		Accumulated			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Equity
March 31, 2022		-	$	-		-	$	-		-	$	-		652,068	$	652	$	54,176,262	$	(44,822,683	)	$	9,354,231

Issuance of common stock and accompanying warrants, net of issuance costs		-		-		-		-		-		-		299,167		299		15,471,476		-			15,471,775
Common stock issued for warrant exercise		-		-		-		-		-		-		444,389		444		1		-			445
Stock-based compensation		-		-		-		-		-		-		-		-		9,062		-			9,062
Net loss		-		-		-		-		-		-		-		-		-		(1,791,144	)		(1,791,144	)

June 30, 2022		-	$	-		-	$	-		-	$	-		1,395,624	$	1,395	$	69,656,801	$	(46,613,827	)	$	23,044,369

The Accompanying notes are an integral part of these condensed consolidated financial statements

Table of Contents

CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

JUNE 30, 2023

NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities.

The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively.

In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

Use of Estimates –The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.

Table of Contents

The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement.

Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.

Table of Contents

Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022.

Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions.

Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities.

Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss.

Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares.

Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.

Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.

Table of Contents

Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

NOTE 2 – LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 43,112 shares of CMTH common stock valued at $100,000. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $4,986 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $26,030. The Company expects to amortize $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a university. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of June 30, 2023, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $586 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $2,619. The Company expects to amortize approximately $1,172 annually through 2025 related to the patent costs.

Lower Back Patent– The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

	·	The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.
	·	In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

	o	$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.
	o	$200,000, upon completion of the IRB clinical trial.
	o	$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

Table of Contents

	o	$100,000 upon filing an IND with the FDA.
	o	$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.
	o	$400,000 upon dosing the first patient in a Phase 3 clinical trial.

Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2020.

The patent expires on May 19, 2027, and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $5,000 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the initial patent license was $40,000. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

The Company has elected to amortize the additional $300,000 associated with the patent over a ten-year period on a straight-line basis. Amortization expense of $22,970 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $133,404. The Company expects to amortize approximately $46,000 annually through 2026 related to the patent costs.

ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor, and as documented in standard operating procedures (SOPs) and other written documentation to augment autologous cells. The terms of the agreement are as follows:

Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)

in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022.

Table of Contents

The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $12,500 were recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $187,500. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.

The following is a rollforward of the Company’s licensing agreements for the six months-ended June 30, 2023.

	Assets		Accumulated Amortization

Balances at December 31, 2022	$	760,000	$	(324,405	)
Addition of new assets				-
Amortization		-		(46,042	)
Balances at June 30, 2023	$	760,000	$	(370,447	)

NOTE 3 – RELATED PARTY TRANSACTIONS

Jadi Cell License Agreement

On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022.

StemSpine Patent Purchase

The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021 the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.

NOTE 4 – DEBT

During the six-months ended June 30, 2023 and 2022 there were no debt issuances.

As of June 30, 2023, and 2022, the Company had no outstanding loans.

NOTE 5 – DERIVATIVE LIABILITIES

As-of June 30, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the six-months ended June 30, 2023 and 2022.

Table of Contents

NOTE 6 – STOCK-BASED COMPENSATION

On September 6, 2021, the Company’s Board of Directors, and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 60,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants, and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success.

During the six-months ended June 30, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 11,182 shares of common stock with an exercise price of $16.90. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. As of June 30, 2023, future estimated stock-based compensation expected to be recorded was estimated to be $58,455. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below.

	Inputs Used

Annual dividend yield	$	-
Expected life (years)		10.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	16.90

During the six-months ended June 30, 2023 and 2022, the fair market value of the options was insignificant to the financial statements.

Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies.

There were no options issued during the six-months ended June 30, 2023, and 11,183 options issued during the six-months ended June 30, 2022.

Option activity for the six-months ended June 30, 2023, consists of the following:

	Stock Options		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		11,183	$	83.96		9.11
Issued		-		-		-
Exercised		-		-		-
Expired		-		-		-
Outstanding, June 30, 2023		11,183	$	83.96		8.61
Vested, June 30, 2023		7,456	$	117.47		8.62

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements.

See Note 7 for warrant rollforward.

Table of Contents

NOTE 7 – STOCKHOLDERS’ EQUITY

May 2022 Private Offering

On May 3, 2022, the Company completed the sale of (i) 299,167 shares of common stock, and pre-funded warrants to purchase 456,389 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 1,511,112 shares of common stock (the “Common Warrants”), at a combined offering price of $22.50 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

The Common Warrants have a five-year term, and an exercise price of $20.00 per share. The Pre-Funded Warrants did not have an expiration date and had an exercise price of $0.001 per share. As of June 30, 2023, all of the Pre-Funded Warrants had been exercised.

The Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, did not embody an obligation for the Company to repurchase its shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants did not provide any guarantee of value or return.

Roth Capital Partners (“Roth”) acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 113,334 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers.

On June 12, 2023 the Company announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up to $2 million of its shares of common stock, in the open market or through privately negotiated transactions, in accordance with applicable securities laws and other restrictions. The manner, timing and amount of any purchase will be based on an evaluation of market conditions, the Company's stock price and other factors. The program has no termination date, may be suspended or discontinued at any time, and does not obligate the Company to acquire any particular number of shares of common stock. As-of June 30, 2023 no shares had been purchased under this program.

Warrants

In connection with our May 2022 private offering, we issued pre-funded warrants to purchase 456,389 shares of common stock and accompanying warrants to purchase 1,624,446 shares of common stock at a price of $20.00 per share.

Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows:

	Range of Inputs Used
Annual dividend yield	$	-
Expected life (years)		5.0
Risk-free interest rate		0.81	%
Expected volatility		92.95	%
Common stock price	$	18.30

As of June 30, 2023, and 2022, warrants to purchase 2,284,932 and 2,296,927 shares of common stock were outstanding respectively.

Warrant activity for the six-months ended June 30, 2023 consists of the following:

	Warrants		Weighted Average Exercise Price		Weighted Average Life Remaining
Outstanding, December 31, 2022		2,284,932	$	26.59		4.22
Issuances		-		-		-
Exercises		-		-		-
Outstanding, June 30, 2023		2,284,932	$	26.59		3.72

Table of Contents

NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

On December 15, 2022, the Company purchased a set of components referred to as “research tools” for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with, pursuant to the terms of an Asset Purchase Agreement between the Company and Narkeshyo. Some of the acquired research tools were originally developed by the former director and current consultant. Under the terms of the agreement, the Company made an initial payment to Narkeshyo in the amount of $2,000,000 upon execution of the agreement, with the remaining amounts to be paid at various times through March 15, 2023, which were made as scheduled. Upon execution of the agreement, the Company recorded $5,000,000 as research and development expenses.

The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products. This acquisition of the research tools aligned with the Company’s priority of advancing and augmenting its suite of cGMP (Current Good Manufacturing Practices) cellular therapy products. The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development. The information contained in the research tools will not only be used to support and fast-track the Company’s regulatory filings (such as IND, NDA, ANDA and export applications), but also, provide clinical and regulatory support to potential partners and collaborators without having to divulge trade secrets and know-how.

A third-party analysis of this acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company’s research and development expenses over the long term.

The purchased tools included (but were not limited to):

	·	Toxicology
	·	Screening
	·	Preclinical Testing
	·	Assays
	·	Authorization
	·	Tools of Biological Transaction
	·	Tools of Intellectual Property

NOTE 9 – SUBSEQUENT EVENTS

There were no material subsequent events during this period.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2022, and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.

Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

Overview

We are a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. Our platforms, therapies and products include the following:

Our subsidiary, Creative Medical Technologies, Inc. (“CMT”), was originally created to monetize U.S. Patent No. 8,372,797 and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired in May 2016. Subsequently, we have expanded our development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, Type-1 diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc. nor AlloCelz LLC have commenced commercial activities.

We currently conduct substantially all of our commercial operations through CMT, which markets and sells our CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem^® and FemCelz^® kits are currently available through physicians at eight locations in the United States.

Table of Contents

In 2020, through our ImmCelz Inc. subsidiary, we began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed/supercharged” by culturing them outside the patient’s body with optimized cell-free factors. The immune cells are then re-injected into the patient from whom they were extracted. We believe this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

In June 2022, we signed an agreement with Greenstone Biosciences Inc. for the development of a human induced pluripotent stem cell (iPSC) pipeline for our ImmCelz® platform. This project was identified as iPScelz™. The efforts by Greenstone Biosciences Inc. are expected to complement and expand our current work on novel therapeutic cell lines.

In October 2022, we announced the development of our AlloStem™ Clinical Cell Line, a proprietary allogenic cell line which includes a Master Cell Bank and a Drug Master File. We believe we will able to use this cell line for many of our programs, including our ImmCelz® immunotherapy platform for multiple diseases, OvaStem® for Premature Ovarian Failure, CELZ-201 for Type 1 diabetes, StemSpine® for lower back pain, and IPScelz ™ inducible pluripotent stem cell program in ongoing development with Greenstone Biosciences.

In November 2022, we announced that the FDA had cleared the Company’s CELZ-201 Investigational New Drug (IND) application for the treatment of Type 1 Diabetes, which will allow us to begin a Phase I/II clinical trial. The primary objective of the study will be to evaluate CELZ-201 in patients with newly diagnosed Type 1 Diabetes. Patient recruitment is expected to begin in 2023.

In February 2023, the Company reported positive three-year follow-up data for its StemSpine® pilot study. The three-year data demonstrates continued efficacy of the StemSpine® procedure for treating chronic lower back pain without any serious adverse effects reported.

In March 2023, the Company announced that it filed an application with the FDA to receive Orphan Drug Designation for the treatment of Brittle Type 1 Diabetes using its ImmCelz®(CELZ-100) platform, and in April 2023, the Company reported positive one-year follow-up data and significant efficacy using CELZ-001 to treat patients with Type 2 Diabetes without any serious adverse effects reported

In addition to our clinical research efforts, we are currently seeking to expand the commercial sale and use of our CaverStem® and FemCelz® products by physicians in the United States.

Results of Operations – For the Three-month Periods Ended June 30, 2023, and 2022

Gross Revenue. We generated no revenue for the three-months ended June 30, 2023 and 2022.

Cost of Goods Sold. We generated no cost of goods sold for the three-months ended June 30, 2023 and 2022.

Gross Profit/(Loss). We generated no gross profit for the three-months ended June 30, 2023 and 2022.

Selling, General and Administrative Expenses. General and administrative expenses for the three-months ended June 30, 2023, totaled $859,537, in comparison with $1,108,428 for the comparable period a year ago. The decrease of $248,891, or 23% is primarily due to a decrease of $90,194 in marketing, $38,152 in travel, $76,000 in timing-related Board of Director expenses and $37,887 in D&O.

Amortization Expenses. Amortization expenses for the three-month periods ended June 30, 2023 and 2022, totaled $23,021.

Research and Development Expenses. Research and development expenses for the three-months ended June 30, 2023, totaled $309,480 in comparison to $659,695 for the comparable period a year ago. The decrease of $350,215, or 53% was primarily due to trial-related start-up expenses of $410,000 incurred in 2022 associated with our CELZ-201 Phase I/II diabetes trial.

Operating Loss. For the reasons stated above, our operating loss for the three-months ended June 30, 2023, was $1,192,038 in comparison with $1,791,144 for the comparable period a year ago.

Table of Contents

Other Income. Other income for the three-months ended June 30, 2023, totaled $89,913 in comparison with $0 for the comparable period a year ago. The increased income of $89,913 is due to increased interest income associated with $9,581,207 in short-term certificates of deposit.

Net Income/Loss. For the reasons stated above, our net loss for the three-months ended June 30, 2023, was $1,102,125 in comparison with a net loss of $1,791,144 for the comparable period a year ago.

Results of Operations – For the Six-month Periods Ended June 30, 2023, and 2022

Gross Revenue. We generated no revenue for the six-months ended June 30, 2023, in comparison with $15,000 for the comparable period a year ago. The pause in sales reflects the Company’s re-evaluation of marketing and distribution options to generate improved sales of the Caverstem and FemCelz procedures.

Cost of Goods Sold. We generated no cost of goods sold for the six-months ended June 30, 2023, in comparison with $6,791 for the comparable period a year ago. The decrease is due to the reduction in sales.

Gross Profit/(Loss). We generated $0 in gross profit for the six-months ended June 30, 2023, in comparison with $8,209 in gross profit for the comparable period a year ago.

Selling, General and Administrative Expenses. General and administrative expenses for the six-months ended June 30, 2023, totaled $1,630,557, in comparison with $2,238,845 for the comparable period a year ago. The decrease of $607,928, or 27% is primarily due to decreases of $194,000 in consulting expenses, $131,136 in marketing expenses, $121,309 in D&O insurance, $76,000 in Board of Directors payment timing, $49,490 in accounting fees, $44,672 in travel, and $32,098 in stock-based compensation.

Amortization Expenses. Amortization expenses for the six-month periods ended June 30, 2023 and 2022, totaled $46,042.

Research and Development Expenses. Research and development expenses for the six-months ended June 30, 2023, totaled $628,500 in comparison to $669,695 for the comparable period a year ago. The decrease of $41,186, or 6% was primarily due to of trial-related start-up expenses in 2022 associated with our CELZ-201 Phase I/II diabetes trial.

Operating Loss. For the reasons stated above, our operating loss for the six-months ended June 30, 2023, was $2,305,108 in comparison with $2,946,013 for the comparable period a year ago.

Other Income. Other income for the six-months ended June 30, 2023, totaled $151,060 in comparison with $0 for the comparable period a year ago. The increased income of $151,060 is due to interest income associated with $9,581,207 in short-term certificates of deposit.

Net Income/Loss. For the reasons stated above, our net loss for the six-months ended June 30, 2023, was $2,154,048 in comparison with a net loss of $2,946,013 for the comparable period a year ago.

Liquidity and Capital Resources

As of June 30, 2023, we had $13,570,757 of available cash and certificates of deposit and positive working capital of approximately $13,336,116. In comparison, as of December 31, 2022, we had $18,399,136 of available cash and positive working capital of $15,425,798.

On May 3, 2022 we received gross proceeds of $17,000,000, before deducting placement agent fees and expenses, upon the closing of an unregistered sale of equity securities of (i) 299,167 shares of our common stock and pre-funded warrants to purchase 456,389 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 1,511,112 shares of common stock at an exercise price of $20.00 per share (“Warrants”), at a combined offering price of $22.50 per share of common stock/Pre-Funded Warrant and related Warrant to a group of institutional investors (the “Purchasers”). The Warrants have a five-year term, and an exercise price of $20.00 per share. The Pre-Funded Warrants do not expire and had an exercise price of $0.001 per share. Roth Capital Partners acted as sole placement agent for the offering. We paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 113,334 shares of common stock with the same terms as the common warrants issued to the purchasers. Pursuant to the Purchase Agreement, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company agreed to file a registration statement with the Securities and Exchange Commission to register the resale of the shares of Common Stock issued in the offering and the shares of Common Stock underlying the Warrants and Pre-Funded Warrants. On May 10, 2022, we filed a Form S-3 registration statement to register the shares, Warrants and Pre-Funded Warrants for resale. The registration went effective on May 19, 2022, fulfilling our contractual obligation. From June through July 2022, all of the Pre-Funded Warrants were exercised for shares of common stock.

Table of Contents

Cash Flows

Net Cash used in Operating Activities. We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $4,828,379 for the six months-ended June 30, 2023, in comparison to $3,332,429 for the comparable period a year ago, an increase of $1,495,950 or 45%. The increase in cash used in operations was primarily related to $3,000,000 in cash payments related to the purchase of research tools referenced in Note 8 offset by reductions in general and administrative expenses.

Net Cash Received in Investing Activities. Cash received in investing activities was $497,410 for the six-months ended June 30, 2023, related to net redemptions of $497,410 in certificates of deposit in comparison to $0 for the six-months ended June 30, 2022.

Net Cash from Financing Activities.

There were no cash proceeds or expenditures from financing activities during the six-months ended June 30, 2023 compared to $15,472,220 for the six-months ended June 30, 2022. The $15,472,220 is related to the May, 2022 financing referenced in Note 7.

Critical Accounting Policies and Estimates

Our consolidated financial statements are prepared in accordance with generally accepted accounting principles accepted in the United States. In connection with the preparation of our financial statements, we are required to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures. We base our assumptions, estimates and judgments on historical experience, current trends, and other factors that management believes to be relevant at the time our consolidated financial statements are prepared. On a regular basis, we review the accounting policies, assumptions, estimates and judgments to ensure that our financial statements are presented fairly and in accordance with GAAP. However, because future events and their effects cannot be determined with certainty, actual results could differ from our assumptions and estimates, and such differences could be material.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a smaller reporting company, we have elected not to provide the disclosure required by this item.

Item 4. Controls and Procedures

Evaluation of disclosure controls and procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were not effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Description of Material Weaknesses

A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a company’s annual or interim financial statements will not be prevented or detected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control over financial reporting that is less severe than a material weakness, yet important enough to merit attention by those responsible for oversight of a company’s financial reporting. In connection with the preparation and audit of the Company’s financial statements for the year ended the December 31, 2022, management identified the following deficiencies that alone or in combination, represent material weaknesses in internal control over financial reporting, the material weaknesses are still present for the six months ended June 30, 2023 and are as follows:

·	Previously, we failed to adequately disclose the transaction in which we purchased research tools for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with.

·	During the year ended December 31, 2022, we did not sufficiently segregate the duties of our officers.

We intend to remediate the deficiencies described above, and take such other action as we deem appropriate to further strengthen our internal control over financial reporting. We are currently in the process of establishing additional review and procedure controls. For instance, subsequent to quarter end we have implemented a policy whereby disbursements over a certain dollar threshold require dual authorization for processing and payment. The Company expects to remediate the deficiencies and obtain operating effectiveness over the next few quarters. However, because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

In October 2022, we terminated an employee for cause. Subsequent to the termination, in December 2022, the employee brought claims against us for breach of contract, wrongful termination and related claims in the Superior Court of the State California (Orange County). The parties have submitted the action for arbitration before JAMS, where it is now pending.

Item 6. Exhibits

Exhibits
3.1.1		Articles of Incorporation of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.1 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
3.1.2		Certificate of Designation of the Series A Preferred Stock of the Company (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on January 16, 2018).
3.1.3		Certificate of Amendment to Certificate of Designation of the Series A Preferred Stock Pursuant to NRS 78.1955, filed with the Secretary of State of the State of Nevada on March 11, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.4		Certificate of Designation of the Series B Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 12, 2021).
3.1.5		Certificate of Designation of the Series C Preferred Stock of the Company, filed March 30, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 2, 2021).
3.1.6		Certificate of Amendment to Articles of Incorporation Pursuant to NRS 78.385 and 78.390, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.7		Certificate of Withdrawal of Certificate of Designation of Series B Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.8		Certificate of Withdrawal of Certificate of Designation of Series C Convertible Preferred Stock, as filed with the Secretary of State of the State of Nevada on November 2, 2021 (incorporated by reference to Exhibit 3.3 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 5, 2021).
3.1.9		Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on November 8, 2021 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on November 9, 2021).
3.10		Certificate of Change Pursuant to NRS 78.209, as filed with the Secretary of State of the State of Nevada on June 1, 2023 (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 9, 2023).
3.2		Bylaws of Creative Medical Technology Holdings, Inc., a Nevada corporation (incorporated by reference to Exhibit 3.2 to the Company’s Form 10 filed with the Securities and Exchange Commission on November 18, 2008).
4.1		Form of Public Warrant issued in December 7, 2021 public offering (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on November 23, 2021).
4.2		Underwriter’s Warrant issued to Roth Capital Partners, LLC dated December 7, 2021 (incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).
4.3		Form of Common Stock Purchase Warrant issued under Securities Purchase Agreement dated as of August 9, 2021 between Creative Medical Technology Holdings, Inc. and the purchasers named therein (incorporated by reference to Exhibit 4.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 12, 2021).
10.1		Patent Purchase Agreement dated May 17, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Health, Inc. (incorporated by reference to Exhibit 10.25 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
10.2		Amendment and Waiver to Patent Purchase Agreement dated November 14, 2017, between Creative Medical Technology Holdings, Inc. and Creative Medical Health, Inc. (incorporated by reference to Exhibit 10.26 to the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 17, 2021).
10.3		Agreement dated December 28, 2020, between Jadi Cell LLC and ImmCelz, Inc. (incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-1 filed with the Securities and Exchange Commission on September 28, 2021).
10.4		Warrant Agency Agreement between Creative Medical Technology Holdings, Inc. and vStock Transfer LLC dated December 7, 2021 (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on December 7, 2021).
10.5†		2021 Equity Incentive Plan (incorporated by reference to Appendix B to the Company’s Information Statement on Schedule 14C filed with the Securities and Exchange Commission on September 24, 2021).
10.6†		Employment Agreement between Creative Medical Technology Holdings, Inc. and Timothy Warbington, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).
10.7†		Employment Agreement between Creative Medical Technology Holdings, Inc. Company and Donald Dickerson, dated as of February 9, 2022. (incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on February 11, 2022).
31.1		Rule 13a-14(a)/15d-14a(a) Certification of Principal Executive Officer*
31.2		Rule 13a-14(a)/15d-14a(a) Certification of Principal Financial Officer*
32.1		Section 1350 Certification of Principal Executive Officer *
32.2		Section 1350 Certification of Principal Financial Officer *
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema Document
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document

________

† Management contract or compensatory plan or arrangement.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	Creative Medical Technology Holdings, Inc.

Date: August 11, 2023	By	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer
		(Principal Executive Officer)

Date: August 11, 2023	By	/s/ Donald Dickerson
		Donald Dickerson, Chief Financial Officer
		(Principal Financial Officer)

EX-31.1 2 celz_ex311.htm CERTIFICATION celz_ex311.htm

EXHIBIT 31.1

CERTIFICATION OF

PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Timothy Warbington, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended June 30, 2023;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financing reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 celz_ex312.htm CERTIFICATION celz_ex312.htm

EXHIBIT 31.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION 302 OF

THE SARBANES-OXLEY ACT OF 2002

I, Donald Dickerson, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Creative Medical Technology Holdings, Inc. for the quarter ended June 30, 2023;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods present in this report;

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involved management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: August 11, 2023	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 celz_ex321.htm CERTIFICATION celz_ex321.htm

EXHIBIT 32.1

CERTIFICATION OF

CHIEF EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Timothy Warbington, Chief Executive Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Quarterly Report on Form 10-Q for the period ended June 30, 2023 fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc

Date: August 11, 2023	By:	/s/ Timothy Warbington
		Timothy Warbington
		Chief Executive Officer
		(Principal Executive Officer)

EX-32.2 5 celz_ex322.htm CERTIFICATION celz_ex322.htm

EXHIBIT 32.2

CERTIFICATION OF

PRINCIPAL FINANCIAL OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350

In connection with this Quarterly Report of Creative Medical Technology Holdings, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), I, Donald Dickerson, Chief Financial Officer of the Company, certify to the best of my knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:

Such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

The information contained in such Quarterly Report on Form 10-Q for the period ended June 30, 2023, fairly presents, in all material respects, the financial condition and results of operations of Creative Medical Technology Holdings, Inc.

Date: August 11, 2023	By:	/s/ Donald Dickerson
		Donald Dickerson
		Chief Financial Officer
		(Principal Financial Officer)

EX-101.SCH 6 celz-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 000008 - Disclosure - LICENSING AGREEMENTS link:presentationLink link:calculationLink link:definitionLink 000009 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 000010 - Disclosure - DEBT link:presentationLink link:calculationLink link:definitionLink 000011 - Disclosure - DERIVATIVE LIABILITIES link:presentationLink link:calculationLink link:definitionLink 000012 - Disclosure - STOCKBASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 000013 - Disclosure - STOCKHOLDERS EQUITY link:presentationLink link:calculationLink link:definitionLink 000014 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE link:presentationLink link:calculationLink link:definitionLink 000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 000017 - Disclosure - LICENSING AGREEMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 000018 - Disclosure - STOCKBASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 000019 - Disclosure - STOCKHOLDERS EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000021 - Disclosure - LICENSING AGREEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000024 - Disclosure - STOCKBASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 000025 - Disclosure - STOCKBASED COMPENSATION (Details 1) link:presentationLink link:calculationLink link:definitionLink 000026 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000027 - Disclosure - STOCKHOLDERS EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 000028 - Disclosure - STOCKHOLDERS EQUITY (Details 1) link:presentationLink link:calculationLink link:definitionLink 000029 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 000030 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 7 celz-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Entity Interactive Data Current CONDENSED CONSOLIDATED BALANCE SHEETS ASSETS CURRENT ASSETS Cash Certificates of deposit Inventory Prepaids and other current assets Total Current Assets [Assets, Current] OTHER ASSETS Other assets Licenses, net of amortization TOTAL ASSETS [Assets] LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Accounts payable Accrued expenses Advances from related party Total Current Liabilities [Liabilities, Current] TOTAL LIABILITIES [Liabilities] Commitments and contingencies STOCKHOLDERS' EQUITY Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,127 and 1,407,625 issued and 1,431,126 and 1,407,624 outstanding at June 30, 2023 and December 31, 2022, respectively Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] Common Stock, Shares Par Value Common Stock, Shares Authorized Common Stock, Shares Issued Common Stock, Shares Outstanding UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Revenues Cost of revenues Gross profit [Gross Profit] OPERATING EXPENSES Research and development Selling, general and administrative Amortization of patent costs TOTAL EXPENSES [Operating Expenses] Operating loss [Operating Income (Loss)] OTHER INCOME/(EXPENSE) Interest income Total other income (expense) [Nonoperating Income (Expense)] LOSS BEFORE PROVISION FOR INCOME TAXES [Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest] Provision for income taxes NET LOSS [Net Income (Loss) Attributable to Parent] NET LOSS PER SHARE - BASIC AND DILUTED WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS CASH FLOWS FROM OPERATING ACTIVITIES: Net loss [Net Income (Loss), Including Portion Attributable to Noncontrolling Interest] Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation Amortization Changes in assets and liabilities: Accounts receivable [Increase (Decrease) in Accounts Receivable] Inventory [Increase (Decrease) in Inventories] Prepaids and other current assets [Increase (Decrease) in Prepaid Expense and Other Assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses [Increase (Decrease) in Accrued Liabilities] Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Investments in certificates of deposit [Payments for Deposits on Real Estate Acquisitions] Redemptions of certificates of deposit Net cash provided by investing activities [Net Cash Provided by (Used in) Investing Activities] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from sale of common stock and warrants, net of issuance costs Proceeds from exercise of warrants Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] NET INCREASE (DECREASE) IN CASH [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect] BEGINNING CASH BALANCE [Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents] ENDING CASH BALANCE SUPPLEMENTAL CASH FLOW INFORMATION: Cash payments for interest Cash payments for income taxes NON-CASH INVESTING AND FINANCING ACTIVITIES: Conversion of management fees and patent liability into common stock UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statement [Table] Statement [Line Items] Equity Components [Axis] Series B, Preferred Stock Series C, Preferred Stock Common Stock Series A, Preferred Stock Additional Paid-In Capital Retained Earnings (Accumulated Deficit) Balance, shares [Shares, Issued] Balance, amount Issuance of common stock and accompanying warrants, net of issuance costs, shares Issuance of common stock and accompanying warrants, net of issuance costs, amount Common stock issued for related party patent liabilities, shares Common stock issued for related party patent liabilities, amount Common stock issued for warrant exercise, shares Common stock issued for warrant exercise, amount Stock-based compensation Net loss Issuance of common stock and accompanying warrants, net of issuance costs, amount [Issuance of common stock and accompanying warrants, net of issuance costs, amount] Round-up shares issued in reverse stock split, shares Round-up shares issued in reverse stock split, amount Balance, shares Balance, amount ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] LICENSING AGREEMENTS LICENSING AGREEMENTS [LICENSING AGREEMENTS] RELATED PARTY TRANSACTIONS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] DEBT DEBT Debt Disclosure [Text Block] DERIVATIVE LIABILITIES DERIVATIVE LIABILITIES Deposit Liabilities Disclosures [Text Block] STOCKBASED COMPENSATION STOCKBASED COMPENSATION Share-Based Payment Arrangement [Text Block] STOCKHOLDERS EQUITY STOCKHOLDERS' EQUITY Stockholders' Equity Note Disclosure [Text Block] SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE Research, Development, and Computer Software Disclosure [Text Block] SUBSEQUENT EVENTS SUBSEQUENT EVENTS Subsequent Events [Text Block] Organization Use Of Estimates Basis Of Presentation Risks And Uncertainties Revenue Concentration Risks Fair Value Of Financial Instruments Basic and Diluted Income (Loss) Per Share Cash Equivalents Inventories Recent Accounting Pronouncements Schedule Of Licensing Agreements Schedule of assumption used in calculation of fair value of options Schedule Of Stock Option Activity Schedule of assumptions used in calcutation of fair value of warrants Schedule of warrant activity Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Options [Member] FDIC insured amount Deferred revenue Reverse split description Additional stock issued Anti-dilutive Securities Excluded From Computation Of Earning Per Share Stock description Assets Beginning Balance [Beginning Balance] Amortization EX-101.CAL 8 celz-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 9 celz-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 10 celz-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 11 celz_10qimg2.jpg begin 644 celz_10qimg2.jpg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�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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.2

Cover - shares
6 Months Ended

Jun. 30, 2023

Aug. 11, 2023

Cover [Abstract]

Entity Registrant Name CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.

Entity Central Index Key 0001187953

Document Type 10-Q

Amendment Flag false

Current Fiscal Year End Date --12-31

Entity Small Business true

Entity Shell Company false

Entity Emerging Growth Company false

Entity Current Reporting Status Yes

Document Period End Date Jun. 30, 2023

Entity Filer Category Non-accelerated Filer

Document Fiscal Period Focus Q2

Document Fiscal Year Focus 2023

Entity Common Stock Shares Outstanding 1,430,530

Document Quarterly Report true

Document Transition Report false

Entity File Number 000-53500

Entity Incorporation State Country Code NV

Entity Tax Identification Number 87-0622284

Entity Address Address Line 1 211 E Osborn Road

Entity Address City Or Town Phoenix

Entity Address State Or Province AZ

Entity Address Postal Zip Code 85012

City Area Code 480

Local Phone Number 399-2822

Security 12b Title Common Stock, par value $0.001 per share

Trading Symbol CELZ

Security Exchange Name NASDAQ

Entity Interactive Data Current Yes

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 308
-Subsection a
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.2

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)

Jun. 30, 2023

Dec. 31, 2022

CURRENT ASSETS

Cash $ 3,989,550 $ 8,320,519

Certificates of deposit 9,581,207 10,078,617

Inventory 10,194 10,194

Prepaids and other current assets 153,692 338,120

Total Current Assets 13,734,643 18,747,450

OTHER ASSETS

Other assets 3,281 3,281

Licenses, net of amortization 389,553 435,595

TOTAL ASSETS 14,127,477 19,186,326

CURRENT LIABILITIES

Accounts payable 344,413 3,267,538

Accrued expenses 39,920 39,920

Advances from related party 14,194 14,194

Total Current Liabilities 398,527 3,321,652

TOTAL LIABILITIES 398,527 3,321,652

STOCKHOLDERS' EQUITY

Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,127 and 1,407,625 issued and 1,431,126 and 1,407,624 outstanding at June 30, 2023 and December 31, 2022, respectively 1,431 1,408

Additional paid-in capital 69,693,425 69,675,124

Accumulated deficit (55,965,906) (53,811,858)

TOTAL STOCKHOLDERS' EQUITY 13,728,950 15,864,674

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 14,127,477 $ 19,186,326

X

- References
No definition available.
+ Details

Name: celz_DueToRelatedPartyCurrent

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.20)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AccruedLiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details

Name: us-gaap_AssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_AssetsCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CertificatesOfDepositAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483154/926-20-50-5

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_FiniteLivedIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_InventoryNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.19-26)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(32))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483467/210-10-45-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481404/852-10-50-7

Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.21)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_LiabilitiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of assets classified as other.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_OtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_OtherAssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of accumulated undistributed earnings (deficit).
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-11

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(17))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares

Jun. 30, 2023

Dec. 31, 2022

CONDENSED CONSOLIDATED BALANCE SHEETS

Common Stock, Shares Par Value $ 0.001 $ 0.001

Common Stock, Shares Authorized 5,000,000 50,000,000

Common Stock, Shares Issued 1,431,127 1,407,625

Common Stock, Shares Outstanding 1,431,126 1,407,624

X

- Definition
Face amount per share of no-par value common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockNoParValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(16)(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: us-gaap_StatementOfFinancialPositionAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Revenues $ 0 $ 0 $ 0 $ 15,000

Cost of revenues 0 0 0 6,791

Gross profit 0 0 0 8,209

OPERATING EXPENSES

Research and development 309,480 659,695 628,509 669,695

Selling, general and administrative 859,537 1,108,428 1,630,557 2,238,485

Amortization of patent costs 23,021 23,021 46,042 46,042

TOTAL EXPENSES 1,192,038 1,791,144 2,305,108 2,954,222

Operating loss (1,192,038) (1,791,144) (2,305,108) (2,946,013)

OTHER INCOME/(EXPENSE)

Interest income 89,913 0 151,060 0

Total other income (expense) 89,913 0 151,060 0

LOSS BEFORE PROVISION FOR INCOME TAXES (1,102,125) (1,791,144) (2,154,048) (2,946,013)

Provision for income taxes 0 0 0 0

NET LOSS $ (1,102,125) $ (1,791,144) $ (2,154,048) $ (2,946,013)

NET LOSS PER SHARE - BASIC AND DILUTED $ (0.78) $ (1.99) $ (1.53) $ (3.81)

WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED 1,409,948 901,125 1,408,793 773,970

X

- References
No definition available.
+ Details

Name: celz_EarningsPerShareBasicsAndDiluted

Namespace Prefix: celz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482686/350-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_GrossProfit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-10

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (a)
-SubTopic 20
-Topic 740
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest income earned from interest bearing assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_InterestIncomeOther

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details

Name: us-gaap_SellingGeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

CASH FLOWS FROM OPERATING ACTIVITIES:

Net loss $ (2,154,048) $ (2,946,013)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation 18,324 50,422

Amortization 46,042 46,042

Changes in assets and liabilities:

Accounts receivable 0 2,485

Inventory 0 (9,759)

Prepaids and other current assets 184,428 (64,960)

Accounts payable (2,923,125) (451,181)

Accrued expenses 0 40,535

Net cash used in operating activities (4,828,379) (3,332,429)

CASH FLOWS FROM INVESTING ACTIVITIES:

Investments in certificates of deposit (4,551,049) 0

Redemptions of certificates of deposit 5,048,459 0

Net cash provided by investing activities 497,410 0

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from sale of common stock and warrants, net of issuance costs 0 15,471,775

Proceeds from exercise of warrants 0 445

Net cash provided by financing activities 0 15,472,220

NET INCREASE (DECREASE) IN CASH (4,330,969) 12,139,791

BEGINNING CASH BALANCE 8,320,519 10,723,870

ENDING CASH BALANCE 3,989,550 22,863,661

SUPPLEMENTAL CASH FLOW INFORMATION:

Cash payments for interest 0 9,186

Cash payments for income taxes 0 0

NON-CASH INVESTING AND FINANCING ACTIVITIES:

Conversion of management fees and patent liability into common stock $ 0 $ 250,000

X

- References
No definition available.
+ Details

Name: celz_ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ProceedsFromIssuanceOfCommonStockAndWarrants

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ProceedsFromRedemptionsOfCertificatesOfDeposit

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482686/350-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-SubTopic 230
-Topic 830
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details

Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccountsReceivable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInAccruedLiabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInInventories

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of increase (decrease) in prepaid expenses, and assets classified as other.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details

Name: us-gaap_InterestPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-24

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NoncashInvestingAndFinancingItemsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details

Name: us-gaap_PaymentsForDepositsOnRealEstateAcquisitions

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(16))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-19

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 33: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J

Reference 34: http://www.xbrl.org/2003/role/exampleRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 4K
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.2

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)

Total

Series B, Preferred Stock

Series C, Preferred Stock

Common Stock

Series A, Preferred Stock

Additional Paid-In Capital

Retained Earnings (Accumulated Deficit)

Balance, shares at Dec. 31, 2021 633,886

Balance, amount at Dec. 31, 2021 $ 10,217,740 $ 0 $ 0 $ 634 $ 0 $ 53,884,920 $ (43,667,814)

Issuance of common stock and accompanying warrants, net of issuance costs, shares 299,167

Issuance of common stock and accompanying warrants, net of issuance costs, amount 15,471,775 0 0 $ 299 0 15,471,476 0

Common stock issued for related party patent liabilities, shares 18,182

Common stock issued for related party patent liabilities, amount 250,000 0 0 $ 18 0 249,982 0

Common stock issued for warrant exercise, shares 444,389

Common stock issued for warrant exercise, amount 445 0 0 $ 444 0 1 0

Stock-based compensation 50,422 0 0 0 0 50,422 0

Net loss (2,946,013) 0 0 $ 0 0 0 (2,946,013)

Balance, shares at Jun. 30, 2022 1,395,624

Balance, amount at Jun. 30, 2022 23,044,369 0 0 $ 1,395 0 69,656,801 (46,613,827)

Balance, shares at Mar. 31, 2022 652,068

Balance, amount at Mar. 31, 2022 9,354,231 0 0 $ 652 0 54,176,262 (44,822,683)

Issuance of common stock and accompanying warrants, net of issuance costs, shares 299,167

Common stock issued for warrant exercise, shares 444,389

Common stock issued for warrant exercise, amount 445 0 0 $ 444 0 1 0

Stock-based compensation 9,062 0 0 0 0 9,062 0

Net loss (1,791,144) 0 0 0 0 0 (1,791,144)

Issuance of common stock and accompanying warrants, net of issuance costs, amount 15,471,775 0 0 $ 299 0 15,471,476 0

Balance, shares at Jun. 30, 2022 1,395,624

Balance, amount at Jun. 30, 2022 23,044,369 0 0 $ 1,395 0 69,656,801 (46,613,827)

Balance, shares at Dec. 31, 2022 1,407,624

Balance, amount at Dec. 31, 2022 15,864,674 0 0 $ 1,408 0 69,675,124 (53,811,858)

Stock-based compensation 18,324 0 0 0 0 18,324 0

Net loss (2,154,048) 0 0 $ 0 0 0 (2,154,048)

Round-up shares issued in reverse stock split, shares 23,502

Round-up shares issued in reverse stock split, amount 0 0 0 $ 23 0 (23) 0

Balance, shares at Jun. 30, 2023 1,431,126

Balance, amount at Jun. 30, 2023 13,728,950 0 0 $ 1,431 0 69,693,425 (55,965,906)

Balance, shares at Mar. 31, 2023 1,407,624

Balance, amount at Mar. 31, 2023 14,821,913 0 0 $ 1,408 0 69,684,286 (54,863,781)

Stock-based compensation 9,162 0 0 0 0 9,162 0

Net loss (1,102,125) 0 0 $ 0 0 0 (1,102,125)

Round-up shares issued in reverse stock split, shares 23,502

Round-up shares issued in reverse stock split, amount 0 0 0 $ 23 0 (23) 0

Balance, shares at Jun. 30, 2023 1,431,126

Balance, amount at Jun. 30, 2023 $ 13,728,950 $ 0 $ 0 $ 1,431 $ 0 $ 69,693,425 $ (55,965,906)

X

- References
No definition available.
+ Details

Name: celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesShares

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodSharesCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodSharesStockWarrantsExercised

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodValueReverseStockSplits

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_StockIssuedDuringPeriodValueStockWarrantsExercised

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of noncash expense for share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (a)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_ShareBasedCompensation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details

Name: us-gaap_SharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Reduction in the number of shares during the period as a result of a reverse stock split.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended

Jun. 30, 2023

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities.

The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively.

In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

Use of Estimates –The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.
The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement.

Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.

Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.
Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022.

Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions.

Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities.

Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss.

Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares.

Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.

Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.
Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 235
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//235/tableOfContent

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 275
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//275/tableOfContent

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//810/tableOfContent

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 250
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent
+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.2

LICENSING AGREEMENTS
6 Months Ended

Jun. 30, 2023

LICENSING AGREEMENTS

LICENSING AGREEMENTS
NOTE 2 – LICENSING AGREEMENTS

ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 43,112 shares of CMTH common stock valued at $100,000. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $4,986 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $26,030. The Company expects to amortize $9,972 annually through 2026 related to the patent costs.

Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a university. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of June 30, 2023, no amounts are currently due to the University.

The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $586 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $2,619. The Company expects to amortize approximately $1,172 annually through 2025 related to the patent costs.

Lower Back Patent– The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following:

·
The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.

·
In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:

o
$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.

o
$200,000, upon completion of the IRB clinical trial.

o
$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.

·
In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:

o
$100,000 upon filing an IND with the FDA.

o
$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.

o
$400,000 upon dosing the first patient in a Phase 3 clinical trial.

·
Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.

·
In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.

·
For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.

The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2020.

The patent expires on May 19, 2027, and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $5,000 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the initial patent license was $40,000. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs.

The Company has elected to amortize the additional $300,000 associated with the patent over a ten-year period on a straight-line basis. Amortization expense of $22,970 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $133,404. The Company expects to amortize approximately $46,000 annually through 2026 related to the patent costs.

ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor, and as documented in standard operating procedures (SOPs) and other written documentation to augment autologous cells. The terms of the agreement are as follows:

·
Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

·
Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”)

·
in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.

To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022.
The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $12,500 were recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $187,500. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs.

The following is a rollforward of the Company’s licensing agreements for the six months-ended June 30, 2023.

Assets

Accumulated
Amortization

Balances at December 31, 2022

$ 760,000

$ (324,405 )
Addition of new assets

-

Amortization

-

(46,042 )
Balances at June 30, 2023

$ 760,000

$ (370,447 )

X

- References
No definition available.
+ Details

Name: celz_LicensingAgreementsAbstract

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_LicensingAgreementsDisclosureTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.2

RELATED PARTY TRANSACTIONS
6 Months Ended

Jun. 30, 2023

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS
NOTE 3 – RELATED PARTY TRANSACTIONS

Jadi Cell License Agreement

On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022.

StemSpine Patent Purchase

The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021 the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash.

X

- References
No definition available.
+ Details

Name: us-gaap_RelatedPartyTransactionsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.2

DEBT
6 Months Ended

Jun. 30, 2023

DEBT

DEBT
NOTE 4 – DEBT

During the six-months ended June 30, 2023 and 2022 there were no debt issuances.

As of June 30, 2023, and 2022, the Company had no outstanding loans.

X

- References
No definition available.
+ Details

Name: us-gaap_DebtDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details

Name: us-gaap_DebtDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.2

DERIVATIVE LIABILITIES
6 Months Ended

Jun. 30, 2023

DERIVATIVE LIABILITIES

DERIVATIVE LIABILITIES
NOTE 5 – DERIVATIVE LIABILITIES

As-of June 30, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the six-months ended June 30, 2023 and 2022.

X

- Definition
The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 405
-Topic 942
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481047/942-405-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-K (SK)
-Number 229
-Section 1406
-Paragraph (e)
-Publisher SEC

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Regulation S-K (SK)
-Number 229
-Section 1406
-Publisher SEC

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03.12)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details

Name: us-gaap_DepositLiabilitiesDisclosuresTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKBASED COMPENSATION
6 Months Ended

Jun. 30, 2023

STOCKBASED COMPENSATION

STOCKBASED COMPENSATION
NOTE 6 – STOCK-BASED COMPENSATION

On September 6, 2021, the Company’s Board of Directors, and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 60,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants, and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success.

During the six-months ended June 30, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 11,182 shares of common stock with an exercise price of $16.90. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. As of June 30, 2023, future estimated stock-based compensation expected to be recorded was estimated to be $58,455. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below.

Inputs
Used

Annual dividend yield

$ -

Expected life (years)

10.0

Risk-free interest rate

0.81 %
Expected volatility

92.95 %
Common stock price

$ 16.90

During the six-months ended June 30, 2023 and 2022, the fair market value of the options was insignificant to the financial statements.

Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies.

There were no options issued during the six-months ended June 30, 2023, and 11,183 options issued during the six-months ended June 30, 2022.

Option activity for the six-months ended June 30, 2023, consists of the following:

Stock
Options

Weighted
Average
Exercise
Price

Weighted
Average
Life
Remaining

Outstanding, December 31, 2022

11,183

$ 83.96

9.11

Issued

-

-

-

Exercised

-

-

-

Expired

-

-

-

Outstanding, June 30, 2023

11,183

$ 83.96

8.61

Vested, June 30, 2023

7,456

$
117.47

8.62

See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements.

See Note 7 for warrant rollforward.

X

- Definition
The entire disclosure for share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//718/tableOfContent

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKHOLDERS EQUITY
6 Months Ended

Jun. 30, 2023

STOCKHOLDERS EQUITY

STOCKHOLDERS' EQUITY
NOTE 7 – STOCKHOLDERS’ EQUITY

May 2022 Private Offering

On May 3, 2022, the Company completed the sale of (i) 299,167 shares of common stock, and pre-funded warrants to purchase 456,389 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 1,511,112 shares of common stock (the “Common Warrants”), at a combined offering price of $22.50 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder.

The Common Warrants have a five-year term, and an exercise price of $20.00 per share. The Pre-Funded Warrants did not have an expiration date and had an exercise price of $0.001 per share. As of June 30, 2023, all of the Pre-Funded Warrants had been exercised.

The Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, did not embody an obligation for the Company to repurchase its shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants did not provide any guarantee of value or return.

Roth Capital Partners (“Roth”) acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 113,334 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers.

On June 12, 2023 the Company announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up to $2 million of its shares of common stock, in the open market or through privately negotiated transactions, in accordance with applicable securities laws and other restrictions. The manner, timing and amount of any purchase will be based on an evaluation of market conditions, the Company's stock price and other factors. The program has no termination date, may be suspended or discontinued at any time, and does not obligate the Company to acquire any particular number of shares of common stock. As-of June 30, 2023 no shares had been purchased under this program.

Warrants

In connection with our May 2022 private offering, we issued pre-funded warrants to purchase 456,389 shares of common stock and accompanying warrants to purchase 1,624,446 shares of common stock at a price of $20.00 per share.

Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows:

Range of
Inputs
Used

Annual dividend yield

$ -

Expected life (years)

5.0

Risk-free interest rate

0.81 %
Expected volatility

92.95 %
Common stock price

$ 18.30

As of June 30, 2023, and 2022, warrants to purchase 2,284,932 and 2,296,927 shares of common stock were outstanding respectively.

Warrant activity for the six-months ended June 30, 2023 consists of the following:

Warrants

Weighted
Average
Exercise
Price

Weighted
Average
Life
Remaining

Outstanding, December 31, 2022

2,284,932

$ 26.59

4.22

Issuances

-

-

-

Exercises

-

-

-

Outstanding, June 30, 2023

2,284,932

$ 26.59

3.72

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for equity.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.2

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE
6 Months Ended

Jun. 30, 2023

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE
NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE

On December 15, 2022, the Company purchased a set of components referred to as “research tools” for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with, pursuant to the terms of an Asset Purchase Agreement between the Company and Narkeshyo. Some of the acquired research tools were originally developed by the former director and current consultant. Under the terms of the agreement, the Company made an initial payment to Narkeshyo in the amount of $2,000,000 upon execution of the agreement, with the remaining amounts to be paid at various times through March 15, 2023, which were made as scheduled. Upon execution of the agreement, the Company recorded $5,000,000 as research and development expenses.

The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products. This acquisition of the research tools aligned with the Company’s priority of advancing and augmenting its suite of cGMP (Current Good Manufacturing Practices) cellular therapy products. The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development. The information contained in the research tools will not only be used to support and fast-track the Company’s regulatory filings (such as IND, NDA, ANDA and export applications), but also, provide clinical and regulatory support to potential partners and collaborators without having to divulge trade secrets and know-how.

A third-party analysis of this acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company’s research and development expenses over the long term.

The purchased tools included (but were not limited to):

·
Toxicology

·
Screening

·
Preclinical Testing

·
Assays

·
Authorization

·
Tools of Biological Transaction

·
Tools of Intellectual Property

X

- References
No definition available.
+ Details

Name: celz_SignificantResearchAndDevelopmentPurchaseAbstract

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483041/730-20-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 985
-SubTopic 730
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//985-730/tableOfContent
+ Details

Name: us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.2

SUBSEQUENT EVENTS
6 Months Ended

Jun. 30, 2023

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS
NOTE 9 – SUBSEQUENT EVENTS

There were no material subsequent events during this period.

X

- References
No definition available.
+ Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//855/tableOfContent

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended

Jun. 30, 2023

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Organization
Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business.

CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities.

The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively.

In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.

Use Of Estimates
Use of Estimates –The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Basis Of Presentation
Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.

Risks And Uncertainties
Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.
The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations.

The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing.

The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones.

On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement.

Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.

Revenue
Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned.

The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.
Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022.

Concentration Risks
Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions.

Fair Value Of Financial Instruments
Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items.

Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy:

Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date.

Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life.

Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.

When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities.

Basic and Diluted Income (Loss) Per Share
Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss.

Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares.

Cash Equivalents
Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.

Inventories
Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.

Recent Accounting Pronouncements
Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

X

- References
No definition available.
+ Details

Name: celz_RisksAndUncertaintiesPolicyTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
No definition available.
+ Details

Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details

Name: us-gaap_CashAndCashEquivalentsPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for credit risk.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 825
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480981/942-825-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
+ Details

Name: us-gaap_ConcentrationRiskCreditRisk

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481203/810-10-50-1
+ Details

Name: us-gaap_ConsolidationPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
+ Details

Name: us-gaap_EarningsPerSharePolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for determining the fair value of financial instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 60
-Paragraph 1
-SubTopic 10
-Topic 820
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482053/820-10-60-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 10
-Topic 825
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-1
+ Details

Name: us-gaap_FairValueOfFinancialInstrumentsPolicy

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483489/210-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(6)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 912
-SubTopic 330
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482105/912-330-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//330/tableOfContent

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483080/330-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 330
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483080/330-10-50-4

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 6
-Subparagraph (a)
-SubTopic 10
-Topic 270
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details

Name: us-gaap_InventoryPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.
+ References
No definition available.
+ Details

Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for revenue from contract with customer.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-17

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 19
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-19

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-18

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 20
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-20

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (e)
-SubTopic 10
-Topic 235
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483426/235-10-50-4

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent
+ Details

Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-9

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-SubTopic 10
-Topic 275
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-12

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details

Name: us-gaap_UseOfEstimates

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.2

LICENSING AGREEMENTS (Tables)
6 Months Ended

Jun. 30, 2023

LICENSING AGREEMENTS

Schedule Of Licensing Agreements

Assets

Accumulated
Amortization

Balances at December 31, 2022

$ 760,000

$ (324,405 )
Addition of new assets

-

Amortization

-

(46,042 )
Balances at June 30, 2023

$ 760,000

$ (370,447 )

X

- References
No definition available.
+ Details

Name: celz_LicensingAgreementsAbstract

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month
+ References
No definition available.
+ Details

Name: celz_ScheduleOfLicensingAgreementsTableTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKBASED COMPENSATION (Tables)
6 Months Ended

Jun. 30, 2023

STOCKBASED COMPENSATION

Schedule of assumption used in calculation of fair value of options

Inputs
Used

Annual dividend yield

$ -

Expected life (years)

10.0

Risk-free interest rate

0.81 %
Expected volatility

92.95 %
Common stock price

$ 16.90

Schedule Of Stock Option Activity

Stock
Options

Weighted
Average
Exercise
Price

Weighted
Average
Life
Remaining

Outstanding, December 31, 2022

11,183

$ 83.96

9.11

Issued

-

-

-

Exercised

-

-

-

Expired

-

-

-

Outstanding, June 30, 2023

11,183

$ 83.96

8.61

Vested, June 30, 2023

7,456

$
117.47

8.62

X

- References
No definition available.
+ Details

Name: celz_ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock

Namespace Prefix: us-gaap_

Data Type: dtr-types:textBlockItemType

Balance Type: na

Period Type: duration

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKHOLDERS EQUITY (Tables)
6 Months Ended

Jun. 30, 2023

STOCKHOLDERS EQUITY

Schedule of assumptions used in calcutation of fair value of warrants

Range of
Inputs
Used

Annual dividend yield

$ -

Expected life (years)

5.0

Risk-free interest rate

0.81 %
Expected volatility

92.95 %
Common stock price

$ 18.30

Schedule of warrant activity

Warrants

Weighted
Average
Exercise
Price

Weighted
Average
Life
Remaining

Outstanding, December 31, 2022

2,284,932

$ 26.59

4.22

Issuances

-

-

-

Exercises

-

-

-

Outstanding, June 30, 2023

2,284,932

$ 26.59

3.72

X

- References
No definition available.
+ Details

Name: celz_ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ScheduleOfWarrantActivityTableTextBlock

Namespace Prefix: celz_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
6 Months Ended

Jun. 30, 2023

Jun. 30, 2022

FDIC insured amount $ 250,000

Deferred revenue $ 40,000 $ 0

Options [Member]

Reverse split description 1-for-10

Additional stock issued 23,502

Anti-dilutive Securities Excluded From Computation Of Earning Per Share 11,183 2,284,932

Stock description 50 million to five million

X

- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details

Name: us-gaap_ConversionOfStockDescription

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details

Name: us-gaap_ConversionOfStockSharesIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(26)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_DeferredRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details

Name: us-gaap_StockholdersEquityReverseStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-SubTopic 405
-Topic 942
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481047/942-405-50-1
+ Details

Name: us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celz_OptionsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.2

LICENSING AGREEMENTS (Details)
6 Months Ended

Jun. 30, 2023

USD ($)

Assets

Beginning Balance $ 760,000

Amortization 0

Ending balance 760,000

Accumulated Amortization

Accumulated Amortization, Beginning Balance (324,405)

Addition of new assets 0

Amortization (46,042)

Accumulated Amortization, Ending Balance $ (370,447)

X

- References
No definition available.
+ Details

Name: celz_AccumulatedAmortization

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_AccumulatedAmortizationAbstract

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_AccumulatedAmortizationAdditionOfNewAssets

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_AccumulatedAmortizationBeginningBalance

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_AccumulatedAmortizationEndingBalance

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_AssetAbstract

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_LicensingAgreements

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_LicensingAgreementsBeginningBalance

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_AdjustmentForAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.2

LICENSING AGREEMENTS (Details Narrative) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended

Dec. 12, 2020

Feb. 28, 2022

Dec. 28, 2020

May 17, 2017

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

Sep. 30, 2021

Jan. 31, 2021

Dec. 31, 2020

Feb. 02, 2016

License fees $ 250,000

No of share Exchange 43,112

Restricted common stock $ 100,000

obligation of the initial payment $ 300,000 $ 300,000 $ 300,000 $ 300,000 $ 300,000

common stock Issue $ 667 8,466 8,929 133,404

Company paid CMH 50,000 50,000 $ 40,000 $ 50,000 $ 50,000

License agreement description (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement

Amortization expenses 23,021 $ 23,021 46,042 $ 46,042

Amortization expenses 22,970 22,970

Number of share issuance of common stock to Jadi Cell 18,018

Carrying value of patent 26,030 26,030

Expected amount of amortization 9,972

Payments upon completion of the IRB clinical trial $ 200,000

Payments in the event of commercialization of technology 300,000

Option [Member]

Initial payment $ 100,000 100,000

Payments upon signing agreement with university for the initiation of an IRB clinical trial 100,000

Payments upon filing an IND with the FDA 100,000

Payments upon dosing of the first patient in a Phase 1-2 clinical trial 200,000

Payments upon dosing of the first patient in Phase 3 clinical trial $ 400,000

Percentage of discount on the basis of recent trading price 30.00%

Share price for two or more consecutive trading days 0.01

Option Warrant [Member]

Royalty payment percentage 5.00%

Non-royalty sublease income percentage 50.00%

License Agreement

Amortization expenses 586 586

Carrying value of patent 2,619 $ 2,619

Expiration period of finite-lived intangible assets 2026

Expected amount of amortization $ 1,172

CMH [Member]

License fees 250,000

Expected annual amortization amount 46,000 46,000

StemSpine LLC [Member]

Amortization expenses 5,000 5,000

Carrying value of patent 40,000 $ 40,000

Expiration period of finite-lived intangible assets May 19, 2027

Expected amount of amortization $ 10,000

Jadi Cell [Member]

Amortization expenses 12,500 $ 12,500

Carrying value of patent $ 187,500 187,500

Expected amount of amortization $ 25,000

X

- References
No definition available.
+ Details

Name: celz_CommonStockIssue

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_CompanyPaid

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_ExpectedAmountOfAmortization

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ExpectedAnnualAmortizationAmount

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_ExpirationPeriodOfFiniteLivedIntangibleAssets

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_InitialPaymentsToAcquireIntangibleAssets

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_LicenseAgreementDescription

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_LicenseFees

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_NoOfShareExchange

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_NonroyaltySubleaseIncomePercentage

Namespace Prefix: celz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_NumberOfShareIssuanceOfCommonStockToJadiCell

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ObligationOfTheInitialPayment

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_PaymentsInTheEventOfCommercializationOfTechnology

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaymentsUponCompletionOfIrbClinicalTrial

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaymentsUponDosingOfFirstPatientInPhase12ClinicalTrial

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaymentsUponFilingIndWithFda

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaymentsUponSigningAgreementWithUniversityForInitiationOfIrbClinicalTrial

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PercentageOfDiscountOnTheBasisOfRecentTradingPrice

Namespace Prefix: celz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_RestrictedCommonStock

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_RoyaltyPaymentPercentage

Namespace Prefix: celz_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_SharePriceForTwoOrMoreConsecutiveTradingDays

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482686/350-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details

Name: us-gaap_AmortizationOfIntangibleAssets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details

Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.
+ References
No definition available.
+ Details

Name: us-gaap_OtherIntangibleAssetsNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsegmentsAxis=celz_WarrantssMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=celz_LicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=celz_CMHMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=celz_StemSpineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=celz_JadiCellMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.2

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
1 Months Ended

Dec. 28, 2020

May 17, 2017

Jun. 30, 2023

Dec. 31, 2022

Sep. 30, 2021

Jan. 31, 2021

Dec. 31, 2020

Dec. 12, 2020

Company Paid Cmh $ 50,000 $ 40,000 $ 50,000 $ 50,000

Obligation Of The Initial Payment $ 300,000 300,000 300,000 300,000

Common Stock Issued 1,431,127 1,407,625

StemSpine Patent Purchase [Member]

Company Paid Cmh $ 50,000 40,000 50,000 50,000

Obligation Of The Initial Payment $ 300,000 $ 300,000 $ 300,000

Common Stock Issued 8,466 8,929 14 667

Long-term Purchase Commitment, Amount $ 100,000

Remaining portion of obligation paid in cash $ 300,000

Jadi Cell License Agreement [Member]

License Fee $ 250,000

Agreement Description the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company

Common Stock Issued 18,018

X

- References
No definition available.
+ Details

Name: celz_AgreementDescription

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_CommonStockIssued1

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_CompanyPaid

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_Licensefee

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_ObligationOfTheInitialPayment

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_RemainingPortionOfObligationPaidInCash

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The minimum amount the entity agreed to spend under the long-term purchase commitment.
+ References
No definition available.
+ Details

Name: us-gaap_LongTermPurchaseCommitmentAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celz_StemSpinePatentPurchaseMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=celz_JadiCellLicenseAgreementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKBASED COMPENSATION (Details)
6 Months Ended

Jun. 30, 2023

$ / shares

Annual dividend yield 0.00%

Expected life (years) 5 years

Common stock price $ 18.30

Option Warrant [Member]

Annual dividend yield 0.00%

Expected volatility 92.95%

Risk-free interest rate 0.81%

Expected life (years) 10 years

Common stock price $ 16.90

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
The risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsegmentsAxis=celz_WarrantssMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKBASED COMPENSATION (Details 1) - Option [Member]
6 Months Ended

Jun. 30, 2023

$ / shares

shares

Stock option, Outstanding at the begining | shares 11,183

Stock option, Outstanding at the end | shares 11,183

Stock option, Vested | shares 7,456

Weighted Average Exercise Price, Outstanding beginning | $ / shares $ 83.96

Weighted Average Exercise Price, Outstanding ending | $ / shares 83.96

Weighted Average Exercise Price, Vested | $ / shares $ 117.47

Weighted Average Life Remaining, Outstanding beginning 9 years 1 month 9 days

Weighted Average Life Remaining, Outstanding ending 8 years 7 months 9 days

Weighted Average Life Remaining, Vested 8 years 7 months 13 days

X

- References
No definition available.
+ Details

Name: celz_WeightedAverageLifeRemainingOutstandingBeginning

Namespace Prefix: celz_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (e)(1)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average grant-date fair value of options vested.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKBASED COMPENSATION (Details Narrative) - USD ($)
6 Months Ended

Jun. 30, 2023

Sep. 06, 2021

Common stock price $ 18.30

Employee Stock Options [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period 10 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 11,182

Common stock price $ 16.90

Stock option, Issued 0

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date

Future estimated stock-based compensation $ 58,455

Employee Stock Options [Member] | Black Scholes Method [Member]

Options vested, value $ 145,525

Board of Directors [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized 60,000

X

- References
No definition available.
+ Details

Name: celz_FutureEstimatedStockBasedCompensation

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_ValueOfOptionsVest

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-3

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details

Name: us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_SubsegmentsAxis=celz_EmployeeStockOptionssMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=celz_BlackScholesMethodMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=celz_BoardOfDirectorsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKHOLDERS EQUITY (Details)
6 Months Ended

Jun. 30, 2023

$ / shares

STOCKHOLDERS EQUITY

Annual dividend yield 0.00%

Expected life (years) 5 years

Risk-free interest rate 0.81%

Expected volatility 92.95%

Common stock price $ 18.30

X

- Definition
The average effective interest rate during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1F
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22(a)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_DebtInstrumentInterestRateDuringPeriod

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-12

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 6.I.Fact.4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1
+ Details

Name: us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate

Namespace Prefix: us-gaap_

Data Type: dtr-types:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKHOLDERS EQUITY (Details 1) - Warrants [Member]
6 Months Ended

Jun. 30, 2023

$ / shares

shares

Warrants, Outstanding Beginning Balance | shares 2,284,932

Warrants, Outstanding Ending Balance | shares 2,284,932

Weighted Average Exercise Price, Outstanding beginning | $ / shares $ 26.59

Weighted Average Exercise Price, Outstanding ending | $ / shares $ 26.59

Weighted Average Life Remaining, Outstanding Beginning 4 years 2 months 19 days

Weighted Average Life Remaining, Outstanding Ending 3 years 8 months 19 days

X

- Definition
Number of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-SubTopic 10
-Topic 718
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: dtr-types:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 718
-SubTopic 10
-Subparagraph (e)(1)
-Name Accounting Standards Codification
-Paragraph 2
-Section 50
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_SubsegmentsAxis=celz_MinimumsssMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.2

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended

May 03, 2022

May 31, 2022

Jun. 30, 2023

Mar. 31, 2022

Amendment description pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder

Sale of shares of common stock 299,167

Pre-Funded Warrants Exercise price $ 0.001

Purchase of warrants shares 456,389

Repurchase of common stock 2,000,000

Purchase of Pre-Funded Warrant and related Common Warrant 1,511,112

Common warrants exercise price $ 20.00

Combined offering price of Pre-Funded Warrant and related Common Warrant $ 22.50

Roth Capital Partners [Member]

Paid placement agent fee $ 1,360,000

Issued warrant to purchase shares of common stock 113,334

Warrants [Member]

Warrants to purchase shares of common stock 1,624,446

Warrant exercise price $ 20.00

Class of Warrant or Right, Outstanding 2,284,932 2,296,927

Private Offering [Member]

Warrants to purchase shares of common stock 456,389

X

- References
No definition available.
+ Details

Name: celz_CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant

Namespace Prefix: celz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_CommonWarrantsExercisePrice

Namespace Prefix: celz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_DescriptionOfAmendment

Namespace Prefix: celz_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_IssuedWarrantToPurchaseSharesOfCommonStock

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PaidPlacementAgentFee

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PreFundedWarrantsExercisePrice

Namespace Prefix: celz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_PurchaseOfPreFundedWarrantAndRelatedCommonWarrant

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_PurchaseOfWarrantsShares

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_RepurchaseOfStock

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- References
No definition available.
+ Details

Name: celz_WarrantExercisePrice

Namespace Prefix: celz_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: celz_WarrantsPurchaseSharesOfCommonStock

Namespace Prefix: celz_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Aggregate number of common shares reserved for future issuance.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details

Name: us-gaap_CommonStockCapitalSharesReservedForFutureIssuance

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_RelatedPartyTransactionAxis=celz_RothCapitalPartnersMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=celz_WarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=celz_PrivateOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.2

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended

Dec. 15, 2022

Jun. 30, 2023

Jun. 30, 2022

Jun. 30, 2023

Jun. 30, 2022

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)

Research and development expenses $ 5,000,000 $ 309,480 $ 659,695 $ 628,509 $ 669,695

Initial payment amount $ 2,000,000

X

- References
No definition available.
+ Details

Name: celz_InitialPaymentAmount

Namespace Prefix: celz_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_ResearchAndDevelopmentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482916/730-10-50-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 912
-SubTopic 730
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482517/912-730-25-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 42 celz_10q_htm.xml IDEA: XBRL DOCUMENT 0001187953 2023-01-01 2023-06-30 0001187953 2022-12-01 2022-12-15 0001187953 celz:WarrantsMember 2022-03-31 0001187953 celz:WarrantsMember 2023-06-30 0001187953 celz:RothCapitalPartnersMember 2023-01-01 2023-06-30 0001187953 2022-05-03 0001187953 celz:WarrantsMember 2022-05-01 2022-05-31 0001187953 celz:PrivateOfferingMember 2022-05-01 2022-05-31 0001187953 2022-05-01 2022-05-03 0001187953 celz:MinimumsssMember 2023-06-30 0001187953 celz:MinimumsssMember 2023-01-01 2023-06-30 0001187953 celz:MinimumsssMember 2022-12-31 0001187953 celz:BlackScholesMethodMember celz:EmployeeStockOptionssMember 2023-01-01 2023-06-30 0001187953 celz:EmployeeStockOptionssMember 2023-06-30 0001187953 celz:EmployeeStockOptionssMember 2023-01-01 2023-06-30 0001187953 celz:BoardOfDirectorsMember 2021-09-06 0001187953 us-gaap:OptionMember 2023-06-30 0001187953 us-gaap:OptionMember 2023-01-01 2023-06-30 0001187953 us-gaap:OptionMember 2022-12-31 0001187953 celz:WarrantssMember 2023-06-30 0001187953 celz:WarrantssMember 2023-01-01 2023-06-30 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-28 0001187953 celz:JadiCellLicenseAgreementMember 2020-12-01 2020-12-28 0001187953 celz:StemSpinePatentPurchaseMember 2017-05-01 2017-05-17 0001187953 celz:StemSpinePatentPurchaseMember 2020-12-12 0001187953 celz:StemSpinePatentPurchaseMember 2021-01-31 0001187953 celz:StemSpinePatentPurchaseMember 2021-09-30 0001187953 celz:StemSpinePatentPurchaseMember 2020-12-31 0001187953 celz:StemSpinePatentPurchaseMember 2017-05-17 0001187953 2017-05-01 2017-05-17 0001187953 us-gaap:OptionMember 2020-12-01 2020-12-12 0001187953 us-gaap:OptionMember 2017-05-01 2017-05-17 0001187953 celz:CMHMember 2023-06-30 0001187953 celz:JadiCellMember 2023-06-30 0001187953 celz:StemSpineMember 2023-06-30 0001187953 celz:LicenseAgreementMember 2023-06-30 0001187953 celz:WarrantssMember 2017-05-01 2017-05-17 0001187953 2022-02-01 2022-02-28 0001187953 celz:JadiCellMember 2023-01-01 2023-06-30 0001187953 celz:StemSpineMember 2023-01-01 2023-06-30 0001187953 celz:LicenseAgreementMember 2023-01-01 2023-06-30 0001187953 celz:JadiCellMember 2022-01-01 2022-06-30 0001187953 celz:StemSpineMember 2022-01-01 2022-06-30 0001187953 celz:LicenseAgreementMember 2022-01-01 2022-06-30 0001187953 2020-12-12 0001187953 2021-01-31 0001187953 2021-09-30 0001187953 2020-12-31 0001187953 2016-02-02 0001187953 celz:CMHMember 2023-01-01 2023-06-30 0001187953 2020-12-01 2020-12-28 0001187953 celz:OptionsMember 2022-01-01 2022-06-30 0001187953 celz:OptionsMember 2023-01-01 2023-06-30 0001187953 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001187953 us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001187953 celz:SeriesCPreferredStocksMember 2023-04-01 2023-06-30 0001187953 celz:SeriesBPreferredStocksMember 2023-04-01 2023-06-30 0001187953 celz:SeriesAPreferredStocksMember 2023-04-01 2023-06-30 0001187953 2023-03-31 0001187953 us-gaap:RetainedEarningsMember 2023-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001187953 us-gaap:CommonStockMember 2023-03-31 0001187953 celz:SeriesCPreferredStocksMember 2023-03-31 0001187953 celz:SeriesBPreferredStocksMember 2023-03-31 0001187953 celz:SeriesAPreferredStocksMember 2023-03-31 0001187953 us-gaap:RetainedEarningsMember 2023-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001187953 us-gaap:CommonStockMember 2023-06-30 0001187953 celz:SeriesCPreferredStocksMember 2023-06-30 0001187953 celz:SeriesBPreferredStocksMember 2023-06-30 0001187953 celz:SeriesAPreferredStocksMember 2023-06-30 0001187953 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001187953 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001187953 celz:SeriesCPreferredStocksMember 2023-01-01 2023-06-30 0001187953 celz:SeriesBPreferredStocksMember 2023-01-01 2023-06-30 0001187953 celz:SeriesAPreferredStocksMember 2023-01-01 2023-06-30 0001187953 us-gaap:RetainedEarningsMember 2022-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001187953 us-gaap:CommonStockMember 2022-12-31 0001187953 celz:SeriesCPreferredStocksMember 2022-12-31 0001187953 celz:SeriesBPreferredStocksMember 2022-12-31 0001187953 celz:SeriesAPreferredStocksMember 2022-12-31 0001187953 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-04-01 2022-06-30 0001187953 us-gaap:CommonStockMember 2022-04-01 2022-06-30 0001187953 celz:SeriesCPreferredStocksMember 2022-04-01 2022-06-30 0001187953 celz:SeriesBPreferredStocksMember 2022-04-01 2022-06-30 0001187953 celz:SeriesAPreferredStocksMember 2022-04-01 2022-06-30 0001187953 2022-03-31 0001187953 us-gaap:RetainedEarningsMember 2022-03-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001187953 us-gaap:CommonStockMember 2022-03-31 0001187953 celz:SeriesCPreferredStocksMember 2022-03-31 0001187953 celz:SeriesBPreferredStocksMember 2022-03-31 0001187953 celz:SeriesAPreferredStocksMember 2022-03-31 0001187953 us-gaap:RetainedEarningsMember 2022-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001187953 us-gaap:CommonStockMember 2022-06-30 0001187953 celz:SeriesCPreferredStocksMember 2022-06-30 0001187953 celz:SeriesBPreferredStocksMember 2022-06-30 0001187953 celz:SeriesAPreferredStocksMember 2022-06-30 0001187953 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001187953 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-06-30 0001187953 us-gaap:CommonStockMember 2022-01-01 2022-06-30 0001187953 celz:SeriesCPreferredStocksMember 2022-01-01 2022-06-30 0001187953 celz:SeriesBPreferredStocksMember 2022-01-01 2022-06-30 0001187953 celz:SeriesAPreferredStocksMember 2022-01-01 2022-06-30 0001187953 us-gaap:RetainedEarningsMember 2021-12-31 0001187953 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001187953 us-gaap:CommonStockMember 2021-12-31 0001187953 celz:SeriesCPreferredStocksMember 2021-12-31 0001187953 celz:SeriesBPreferredStocksMember 2021-12-31 0001187953 celz:SeriesAPreferredStocksMember 2021-12-31 0001187953 2022-06-30 0001187953 2021-12-31 0001187953 2022-01-01 2022-06-30 0001187953 2022-04-01 2022-06-30 0001187953 2023-04-01 2023-06-30 0001187953 2022-12-31 0001187953 2023-06-30 0001187953 2023-08-11 iso4217:USD shares iso4217:USD shares pure 0001187953 false --12-31 Q2 2023 0.001 0 586 5000 12500 22970 0 0 0 10-Q true 2023-06-30 false 000-53500 CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. NV 87-0622284 211 E Osborn Road Phoenix AZ 85012 480 399-2822 Common Stock, par value $0.001 per share CELZ NASDAQ Yes Yes Non-accelerated Filer true false false 1430530 3989550 8320519 9581207 10078617 10194 10194 153692 338120 13734643 18747450 3281 3281 389553 435595 14127477 19186326 344413 3267538 39920 39920 14194 14194 398527 3321652 398527 3321652 0.001 5000000 50000000 1431127 1407625 1431126 1407624 1431 1408 69693425 69675124 -55965906 -53811858 13728950 15864674 14127477 19186326 0 0 0 15000 0 0 0 6791 0 0 0 8209 309480 659695 628509 669695 859537 1108428 1630557 2238485 23021 23021 46042 46042 1192038 1791144 2305108 2954222 -1192038 -1791144 -2305108 -2946013 89913 0 151060 0 89913 0 151060 0 -1102125 -1791144 -2154048 -2946013 0 0 0 0 -1102125 -1791144 -2154048 -2946013 -0.78 -1.99 -1.53 -3.81 1409948 901125 1408793 773970 2154048 2946013 18324 50422 46042 46042 0 -2485 0 9759 -184428 64960 -2923125 -451181 0 40535 -4828379 -3332429 4551049 0 5048459 0 497410 0 0 15471775 0 445 0 15472220 -4330969 12139791 8320519 10723870 3989550 22863661 0 9186 0 0 0 250000 0 0 0 1407624 1408 69675124 -53811858 15864674 0 0 0 23502 23 -23 0 0 0 0 0 0 18324 0 18324 0 0 0 0 0 -2154048 -2154048 0 0 0 1431126 1431 69693425 -55965906 13728950 0 0 0 1407624 1408 69684286 -54863781 14821913 0 0 0 23502 23 -23 0 0 0 0 0 0 9162 0 9162 0 0 0 0 0 -1102125 -1102125 0 0 0 1431126 1431 69693425 -55965906 13728950 0 0 0 633886 634 53884920 -43667814 10217740 0 0 0 299167 299 15471476 0 15471775 0 0 0 18182 18 249982 0 250000 0 0 0 444389 444 1 0 445 0 0 0 0 50422 0 50422 0 0 0 0 0 -2946013 -2946013 0 0 0 1395624 1395 69656801 -46613827 23044369 0 0 0 652068 652 54176262 -44822683 9354231 0 0 0 299167 299 15471476 0 15471775 0 0 0 444389 444 1 0 445 0 0 0 0 9062 0 9062 0 0 0 0 0 -1791144 -1791144 0 0 0 1395624 1395 69656801 -46613827 23044369 NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. Use of Estimates –The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations. Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022. Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions. Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities. Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss. Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares. Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method. Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration. Use of Estimates –The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented. Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations.The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations. Revenue - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer.Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022. 40000 Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions. 250000 Fair Value of Financial Instrument – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities. Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss. Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares. 11183 2284932 1-for-10 50 million to five million 23502 Cash Equivalents – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method. Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis. Recent Accounting Pronouncements – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements. NOTE 2 – LICENSING AGREEMENTS ED Patent – The Company acquired a patent from CMH, a related company on February 2, 2016, in exchange for 43,112 shares of CMTH common stock valued at $100,000. The patent expires in 2025 and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $4,986 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $26,030. The Company expects to amortize $9,972 annually through 2026 related to the patent costs. Multipotent Amniotic Fetal Stem Cells License Agreement - On August 25, 2016, CMT entered into a License Agreement dated August 25, 2016, with a university. This license agreement grants to CMT the exclusive right to all products derived from a patent for use of multipotent amniotic fetal stem cells composition of matter throughout the world during the period ending on the expiration date of the longest-lived patent rights under the patent. The license agreement also permits CMT to grant sublicenses. Under the terms of the license agreement, CMT is required to diligently develop, manufacture, and sell any products licensed under the agreement. CMT paid the University an initial license fee within 30 days of entering into the agreement. CMT is also required to pay annual license maintenance fees on each anniversary date of the agreement, which maintenance fees would be credited toward any earned royalties for any given period. The License Agreement provides for payment of various milestone payments and earned royalties on the net sales of licensed products by CMT or any sub licensee. CMT is also required to reimburse the University for any future costs associated with maintaining the patent. CMT may terminate the license agreement for any reason upon 90 days’ written notice and the University may terminate the agreement in the event CMT fails to meet its obligations set forth therein, unless the breach is cured within 30 days of the notice from the University specifying the breach. CMT is also obligated to indemnify the University against claims arising due to the exercise of the license by CMT or any sub licensee. As of June 30, 2023, no amounts are currently due to the University. The Company estimates that the patent expires in February 2026 and has elected to amortize the patent through the period of expiration on a straight-line basis. Amortization expense of $586 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $2,619. The Company expects to amortize approximately $1,172 annually through 2025 related to the patent costs. Lower Back Patent– The Company, through its subsidiary StemSpine, LLC, acquired a patent from CMH, a related company, on May 17, 2017, covering the use of various stem cells for the treatment of lower back pain from pursuant to a Patent Purchase Agreement, which was amended in November 2017. As amended, the agreement provides the following: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">The Company is required to pay CMH $100,000 within 30 days of demand as an initial payment.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of autologous cells, the Company will pay CMH:</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;vertical-align:top;">o </td><td style="vertical-align:top;">$100,000 upon the signing agreement with a university for the initiation of an IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000, upon completion of the IRB clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$300,000 in the event we commercialize the technology via use of autologous cells by a physician without a clinical trial.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">In the event the Company determines to pursue the technology via use of allogenic cells, the Company will pay CMH:</td></tr></tbody></table><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:8%;"> </td><td style="width:4%;">o </td><td style="vertical-align:top;">$100,000 upon filing an IND with the FDA.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$200,000 upon dosing of the first patient in a Phase 1-2 clinical trial.</td></tr><tr style="height:15px"><td> </td><td>o </td><td style="vertical-align:top;">$400,000 upon dosing the first patient in a Phase 3 clinical trial.</td></tr></tbody></table> <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td style="vertical-align:top;">Payment may be made in cash or shares of our common at a discount of 30% to the lowest closing price within 20 business days prior to the conversion date.</td></tr><tr style="height:15px"><td> </td><td>·</td><td style="vertical-align:top;">In the event the Company’s shares of common stock trade below $0.01 per share for two or more consecutive trading days, the number of any shares issuable as payment doubles.</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">For a period of five years from the date of the first sale of any product derived from the patent, the Company is required to make royalty payments of 5% from gross sales of products, and 50% of sale price or ongoing payments from third parties for licenses granted under the patent to third parties.</td></tr></tbody></table> The Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021, the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation was paid in cash in 2020. The patent expires on May 19, 2027, and the Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expense of $5,000 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the initial patent license was $40,000. The Company expects to amortize approximately $10,000 annually through 2027 related to the patent costs. The Company has elected to amortize the additional $300,000 associated with the patent over a ten-year period on a straight-line basis. Amortization expense of $22,970 was recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $133,404. The Company expects to amortize approximately $46,000 annually through 2026 related to the patent costs. ImmCelz™ - On December 28, 2020, ImmCelz, Inc. (“ImmCelz”), a newly formed Nevada corporation and wholly owned subsidiary of the Company, entered into a Patent License Agreement dated December 28, 2020 (the “Agreement”), with Jadi Cell, LLC. (“Jadi”), a company controlled by Dr. Amit Patel, a former director of the Company. The Agreement grants to ImmCelz™ the patent rights under U.S. Patent# 9,803,176 B2, “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses”. The contract grants ImmCelz™ access to proprietary process of expanding the master cell bank of Jadi Cell LLC, as currently practiced by Licensor, and as documented in standard operating procedures (SOPs) and other written documentation to augment autologous cells. The terms of the agreement are as follows: <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;vertical-align:top;">·</td><td style="vertical-align:top;">Licensee shall pay Licensor a license fee of $250,000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement</td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">Within thirty (30) days of the end of each calendar quarter during the term of this Agreement, Licensee will pay Licensor five percent (5%) of the Net Income of ImmCelz™. during such calendar quarter (the “Continuing Royalty”) </td></tr><tr style="height:15px"><td> </td><td style="vertical-align:top;">·</td><td style="vertical-align:top;">in one or a series of related transactions, of all or substantially all of the business or assets of Licensee ImmCelz, Inc. (“Sale of Assets”) will result in a one-time ten-percent allocation to the licensor, the Continuing Royalty will be calculated at five percent (5%) of the Net Income of Licensee in any calendar quarter in which the Net Income in such calendar quarter reflects the receipt of any consideration from such Sale of Assets.</td></tr></tbody></table> To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022. The Company has elected to amortize the patent over a ten-year period on a straight-line basis. Amortization expenses of $12,500 were recorded for the six-months ended June 30, 2023, and 2022. As of June 30, 2023, the carrying value of the patent was $187,500. The Company expects to amortize approximately $25,000 annually through 2030 related to the patent costs. The following is a rollforward of the Company’s licensing agreements for the six months-ended June 30, 2023. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(324,405 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(46,042 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(370,447 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 43112 100000 26030 9972 2026 586 2619 1172 100000 100000 200000 300000 100000 200000 400000 0.30 0.01 0.05 0.50 100000 50000 667 50000 300000 40000 300000 8466 50000 300000 8929 300000 May 19, 2027 5000 40000 10000 22970 133404 46000 250000 (the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement 250000 18018 12500 187500 25000 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Assets</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">AccumulatedAmortization</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Balances at December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(324,405 </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Addition of new assets</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Amortization</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(46,042 </td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Balances at June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">760,000</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(370,447 </td><td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr></tbody></table> 760000 -324405 0 0 -46042 760000 -370447 NOTE 3 – RELATED PARTY TRANSACTIONS Jadi Cell License Agreement On December 28, 2020, the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company. The agreement provides Company with an exclusive, worldwide license to U.S. Patent No. 9,803,176 “Methods and compositions for the clinical derivation of an allogenic cell and therapeutic uses” and the proprietary process of expanding the master cell bank of Jadi Cell LLC, in the field of enhancing autologous cells. The agreement is described in detail in Note 2 above. To date, the Company has not made any payments to Jadi Cell under this agreement, other than the $250,000 initial license fee, which was paid by the issuance of 18,018 shares of common stock to Jadi Cell in February 2022. StemSpine Patent Purchase The Company acquired U.S. Patent No. 9,598,673 covering the use of various stem cells for the treatment of lower back pain from its affiliate CMH pursuant to a Patent Purchase Agreement dated May 17, 2017, which was amended in November 2017. The inventors of the patent were Thomas Ichim, PhD and Amit Patel, MD, former directors of the Company, and Annette Marleau, PhD. The Patent Purchase Agreement is described in detail in Note 2 above. Pursuant to the Patent Purchase Agreement, the Company paid CMH the $100,000 obligation of the initial payment due under this agreement, by a $50,000 cash payment and the issuance of 667 shares of common stock on December 12, 2020. On December 31, 2020, following the Company’s announcement with respect to the clinical commercialization of the StemSpine technology, the Company paid CMH $50,000 of the $300,000 obligation due under this agreement through the issuance of 14 shares of common stock. On September 30, 2021 the Company paid CMH an additional $40,000 of the $300,000 obligation due under this agreement through the issuance of 8,466 shares of common stock, and in January 2021 the Company paid CMH an additional $50,000 of the $300,000 obligation due under this agreement through the issuance of 8,929 shares of common stock. The remaining portion of the $300,000 obligation has been paid in cash. the Company entered into a patent license agreement with Jadi Cell, LLC, a company owned and controlled by Dr. Amit Patel, a former director of the Company 250000 18018 100000 50000 667 50000 300000 14 40000 300000 8466 50000 300000 8929 300000 NOTE 4 – DEBT During the six-months ended June 30, 2023 and 2022 there were no debt issuances. As of June 30, 2023, and 2022, the Company had no outstanding loans. NOTE 5 – DERIVATIVE LIABILITIES As-of June 30, 2023 and 2022, the Company had no outstanding derivative liabilities and there was no derivative activity during the six-months ended June 30, 2023 and 2022. NOTE 6 – STOCK-BASED COMPENSATION On September 6, 2021, the Company’s Board of Directors, and holders of a majority of the voting power of the Company’s stockholders approved the Company’s 2021 Equity Incentive Plan (the “2021 Plan”) and reserved 60,000 shares of common stock for the issuance of awards thereunder. The 2021 Plan provides for the granting to our employees, officers, directors, consultants, and advisors of performance awards payable in shares of common stock, stock options (non-statutory and incentive), restricted stock awards, stock appreciation rights (“SARs”), restricted share units (“RSUs”) and other stock-based awards. The purpose of the 2021 Plan is to secure for the Company and its stockholders the benefits arising from capital stock ownership by eligible participants who are expected to contribute to the Company’s future growth and success. During the six-months ended June 30, 2022, Messrs. Warbington and Dickerson received 10-year options to purchase an aggregate of 11,182 shares of common stock with an exercise price of $16.90. The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date. As of June 30, 2023, future estimated stock-based compensation expected to be recorded was estimated to be $58,455. The value of the options was determined to be $145,525 based upon the Black-Scholes method, see variables used below. <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.90</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> During the six-months ended June 30, 2023 and 2022, the fair market value of the options was insignificant to the financial statements. Since the expected life of the options was greater than the Company’s historical stock information available, the Company determined the expected volatility based on price fluctuations of comparable public companies. There were no options issued during the six-months ended June 30, 2023, and 11,183 options issued during the six-months ended June 30, 2022. Option activity for the six-months ended June 30, 2023, consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,183</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">83.96</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.11</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,183</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">83.96</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.61</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,456</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">117.47</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.62</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> See Note 2 for discussion related to the issuance of common stock in connection with licensing agreements. See Note 7 for warrant rollforward. 60000 P10Y 11182 16.90 The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date 58455 145525 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Inputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px"><td> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" colspan="2" style="width:9%;"> </td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">16.90</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> P10Y 0.0081 0.9295 16.90 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Stock Options</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,183</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">83.96</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">9.11</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issued</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercised</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expired</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">11,183</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">83.96</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.61</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Vested, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">7,456</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">117.47</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">8.62</td><td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 11183 83.96 P9Y1M9D 11183 83.96 P8Y7M9D 7456 117.47 P8Y7M13D NOTE 7 – STOCKHOLDERS’ EQUITY May 2022 Private Offering On May 3, 2022, the Company completed the sale of (i) 299,167 shares of common stock, and pre-funded warrants to purchase 456,389 shares of common stock (the “Pre-Funded Warrants”), and (ii) accompanying warrants to purchase 1,511,112 shares of common stock (the “Common Warrants”), at a combined offering price of $22.50 per share of common stock/Pre-Funded Warrant and related Common Warrant, to a group of institutional investors (the “Purchasers”), pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder. The Common Warrants have a five-year term, and an exercise price of $20.00 per share. The Pre-Funded Warrants did not have an expiration date and had an exercise price of $0.001 per share. As of June 30, 2023, all of the Pre-Funded Warrants had been exercised. The Pre-Funded Warrants were classified as a component of permanent equity because they are freestanding financial instruments that are legally detachable and separately exercisable from the shares of common stock with which they were issued, are immediately exercisable, did not embody an obligation for the Company to repurchase its shares, and permitted the holders to receive a fixed number of shares of common stock upon exercise. In addition, the Pre-Funded Warrants did not provide any guarantee of value or return. Roth Capital Partners (“Roth”) acted as sole placement agent for the offering. The Company paid Roth a placement agent fee in the amount of $1,360,000 and issued Roth a warrant to purchase 113,334 shares of Common Stock with the same terms as the Common Warrants issued to the Purchasers. On June 12, 2023 the Company announced that its Board of Directors has approved a share repurchase program. The program authorizes the Company to repurchase up to $2 million of its shares of common stock, in the open market or through privately negotiated transactions, in accordance with applicable securities laws and other restrictions. The manner, timing and amount of any purchase will be based on an evaluation of market conditions, the Company's stock price and other factors. The program has no termination date, may be suspended or discontinued at any time, and does not obligate the Company to acquire any particular number of shares of common stock. As-of June 30, 2023 no shares had been purchased under this program. Warrants In connection with our May 2022 private offering, we issued pre-funded warrants to purchase 456,389 shares of common stock and accompanying warrants to purchase 1,624,446 shares of common stock at a price of $20.00 per share. Assumptions used in calculating the fair value of the warrants issued in 2022 were as follows: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Range ofInputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.30</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> As of June 30, 2023, and 2022, warrants to purchase 2,284,932 and 2,296,927 shares of common stock were outstanding respectively. Warrant activity for the six-months ended June 30, 2023 consists of the following: <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,284,932</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.59</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.22</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,284,932</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26.59</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.72</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 299167 456389 1511112 22.50 pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder 20.00 0.001 1360000 113334 2000000 456389 1624446 20.00 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Range ofInputs Used</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Annual dividend yield</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected life (years)</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Risk-free interest rate</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.81</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Expected volatility</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">92.95</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Common stock price</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">18.30</td><td style="width:1%;white-space: nowrap;"> </td></tr></tbody></table> P5Y 0.0081 0.9295 18.30 2284932 2296927 <table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Warrants</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Exercise Price</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td><td style="white-space: nowrap;"> </td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;">Weighted Average Life Remaining</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Outstanding, December 31, 2022</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,284,932</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.59</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.22</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Issuances</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;">Exercises</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"> </td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;">Outstanding, June 30, 2023</td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,284,932</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">26.59</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td><td style="width:1%;white-space: nowrap;"> </td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> </td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3.72</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> </td></tr></tbody></table> 2284932 26.59 P4Y2M19D 2284932 26.59 P3Y8M19D NOTE 8 – SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE On December 15, 2022, the Company purchased a set of components referred to as “research tools” for $5,000,000 from Narkeshyo LLC, an entity a former director and current consultant of the Company is affiliated with, pursuant to the terms of an Asset Purchase Agreement between the Company and Narkeshyo. Some of the acquired research tools were originally developed by the former director and current consultant. Under the terms of the agreement, the Company made an initial payment to Narkeshyo in the amount of $2,000,000 upon execution of the agreement, with the remaining amounts to be paid at various times through March 15, 2023, which were made as scheduled. Upon execution of the agreement, the Company recorded $5,000,000 as research and development expenses. The vision and pipeline of the Company is based on robust and thorough development of its biological platforms, therapies and products. This acquisition of the research tools aligned with the Company’s priority of advancing and augmenting its suite of cGMP (Current Good Manufacturing Practices) cellular therapy products. The Company believes that the acquired research tools will allow it to protect its intellectual property while complying with regulatory requirements, and accelerate product development. The information contained in the research tools will not only be used to support and fast-track the Company’s regulatory filings (such as IND, NDA, ANDA and export applications), but also, provide clinical and regulatory support to potential partners and collaborators without having to divulge trade secrets and know-how. A third-party analysis of this acquisition concluded it would accelerate development time by 3-5 years and result in a substantial reduction in the Company’s research and development expenses over the long term. The purchased tools included (but were not limited to): <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"> </td><td style="width:4%;">·</td><td>Toxicology </td></tr><tr style="height:15px"><td> </td><td>· </td><td>Screening</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Preclinical Testing</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Assays</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Authorization</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Tools of Biological Transaction</td></tr><tr style="height:15px"><td> </td><td>·</td><td>Tools of Intellectual Property</td></tr></tbody></table> 2000000 5000000 NOTE 9 – SUBSEQUENT EVENTS There were no material subsequent events during this period. EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 123 200 1 false 22 0 false 4 false false R1.htm 000001 - Document - Cover Sheet http://celz.com/role/Cover Cover Cover 1 false false R2.htm 000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://celz.com/role/CondensedConsolidatedBalanceSheets CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 5 false false R6.htm 000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 6 false false R7.htm 000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 7 false false R8.htm 000008 - Disclosure - LICENSING AGREEMENTS Sheet http://celz.com/role/LicensingAgreements LICENSING AGREEMENTS Notes 8 false false R9.htm 000009 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://celz.com/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 9 false false R10.htm 000010 - Disclosure - DEBT Sheet http://celz.com/role/DEBT DEBT Notes 10 false false R11.htm 000011 - Disclosure - DERIVATIVE LIABILITIES Sheet http://celz.com/role/DerivativeLiabilities DERIVATIVE LIABILITIES Notes 11 false false R12.htm 000012 - Disclosure - STOCKBASED COMPENSATION Sheet http://celz.com/role/StockbasedCompensation STOCKBASED COMPENSATION Notes 12 false false R13.htm 000013 - Disclosure - STOCKHOLDERS EQUITY Sheet http://celz.com/role/StockholdersEquity STOCKHOLDERS EQUITY Notes 13 false false R14.htm 000014 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE Sheet http://celz.com/role/SignificantResearchAndDevelopmentPurchase SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE Notes 14 false false R15.htm 000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://celz.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 000017 - Disclosure - LICENSING AGREEMENTS (Tables) Sheet http://celz.com/role/LicensingAgreementsTables LICENSING AGREEMENTS (Tables) Tables http://celz.com/role/LicensingAgreements 17 false false R18.htm 000018 - Disclosure - STOCKBASED COMPENSATION (Tables) Sheet http://celz.com/role/StockbasedCompensationTables STOCKBASED COMPENSATION (Tables) Tables http://celz.com/role/StockbasedCompensation 18 false false R19.htm 000019 - Disclosure - STOCKHOLDERS EQUITY (Tables) Sheet http://celz.com/role/StockholdersEquityTables STOCKHOLDERS EQUITY (Tables) Tables http://celz.com/role/StockholdersEquity 19 false false R20.htm 000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies 20 false false R21.htm 000021 - Disclosure - LICENSING AGREEMENTS (Details) Sheet http://celz.com/role/LicensingAgreementsDetails LICENSING AGREEMENTS (Details) Details http://celz.com/role/LicensingAgreementsTables 21 false false R22.htm 000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative) Sheet http://celz.com/role/LicensingAgreementsDetailsNarrative LICENSING AGREEMENTS (Details Narrative) Details http://celz.com/role/LicensingAgreementsTables 22 false false R23.htm 000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://celz.com/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://celz.com/role/RelatedPartyTransactions 23 false false R24.htm 000024 - Disclosure - STOCKBASED COMPENSATION (Details) Sheet http://celz.com/role/StockbasedCompensationDetails STOCKBASED COMPENSATION (Details) Details http://celz.com/role/StockbasedCompensationTables 24 false false R25.htm 000025 - Disclosure - STOCKBASED COMPENSATION (Details 1) Sheet http://celz.com/role/StockbasedCompensationDetails1 STOCKBASED COMPENSATION (Details 1) Details http://celz.com/role/StockbasedCompensationTables 25 false false R26.htm 000026 - Disclosure - STOCKBASED COMPENSATION (Details Narrative) Sheet http://celz.com/role/StockbasedCompensationDetailsNarrative STOCKBASED COMPENSATION (Details Narrative) Details http://celz.com/role/StockbasedCompensationTables 26 false false R27.htm 000027 - Disclosure - STOCKHOLDERS EQUITY (Details) Sheet http://celz.com/role/StockholdersEquityDetails STOCKHOLDERS EQUITY (Details) Details http://celz.com/role/StockholdersEquityTables 27 false false R28.htm 000028 - Disclosure - STOCKHOLDERS EQUITY (Details 1) Sheet http://celz.com/role/StockholdersEquityDetails1 STOCKHOLDERS EQUITY (Details 1) Details http://celz.com/role/StockholdersEquityTables 28 false false R29.htm 000029 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative) Sheet http://celz.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS EQUITY (Details Narrative) Details http://celz.com/role/StockholdersEquityTables 29 false false R30.htm 000030 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) Sheet http://celz.com/role/SignificantResearchAndDevelopmentPurchasesDetailsNarrative SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) Details http://celz.com/role/SignificantResearchAndDevelopmentPurchase 30 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:AmortizationOfIntangibleAssets, us-gaap:CommonStockNoParValue, us-gaap:DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1, us-gaap:DeferredRevenue, us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense, us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate - celz_10q.htm 1 celz_10q.htm celz-20230630.xsd celz-20230630_cal.xml celz-20230630_def.xml celz-20230630_lab.xml celz-20230630_pre.xml celz_ex311.htm celz_ex312.htm celz_ex321.htm celz_ex322.htm celz_10qimg2.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "celz_10q.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 328, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 123, "dts": { "calculationLink": { "local": [ "celz-20230630_cal.xml" ] }, "definitionLink": { "local": [ "celz-20230630_def.xml" ] }, "inline": { "local": [ "celz_10q.htm" ] }, "labelLink": { "local": [ "celz-20230630_lab.xml" ] }, "presentationLink": { "local": [ "celz-20230630_pre.xml" ] }, "schema": { "local": [ "celz-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 275, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 9, "http://xbrl.sec.gov/dei/2023": 5, "total": 14 }, "keyCustom": 67, "keyStandard": 133, "memberCustom": 18, "memberStandard": 4, "nsprefix": "celz", "nsuri": "http://celz.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://celz.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "strong", "span", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000010 - Disclosure - DEBT", "menuCat": "Notes", "order": "10", "role": "http://celz.com/role/DEBT", "shortName": "DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000011 - Disclosure - DERIVATIVE LIABILITIES", "menuCat": "Notes", "order": "11", "role": "http://celz.com/role/DerivativeLiabilities", "shortName": "DERIVATIVE LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DepositLiabilitiesDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000012 - Disclosure - STOCKBASED COMPENSATION", "menuCat": "Notes", "order": "12", "role": "http://celz.com/role/StockbasedCompensation", "shortName": "STOCKBASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000013 - Disclosure - STOCKHOLDERS EQUITY", "menuCat": "Notes", "order": "13", "role": "http://celz.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000014 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE", "menuCat": "Notes", "order": "14", "role": "http://celz.com/role/SignificantResearchAndDevelopmentPurchase", "shortName": "SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000015 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "15", "role": "http://celz.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000016 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "16", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ConsolidationPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfLicensingAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000017 - Disclosure - LICENSING AGREEMENTS (Tables)", "menuCat": "Tables", "order": "17", "role": "http://celz.com/role/LicensingAgreementsTables", "shortName": "LICENSING AGREEMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfLicensingAgreementsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000018 - Disclosure - STOCKBASED COMPENSATION (Tables)", "menuCat": "Tables", "order": "18", "role": "http://celz.com/role/StockbasedCompensationTables", "shortName": "STOCKBASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000019 - Disclosure - STOCKHOLDERS EQUITY (Tables)", "menuCat": "Tables", "order": "19", "role": "http://celz.com/role/StockholdersEquityTables", "shortName": "STOCKHOLDERS EQUITY (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://celz.com/role/CondensedConsolidatedBalanceSheets", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "20", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TimeDepositsAtOrAboveFDICInsuranceLimit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfLicensingAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "celz:LicensingAgreements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000021 - Disclosure - LICENSING AGREEMENTS (Details)", "menuCat": "Details", "order": "21", "role": "http://celz.com/role/LicensingAgreementsDetails", "shortName": "LICENSING AGREEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfLicensingAgreementsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "celz:LicensingAgreements", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2020-12-01to2020-12-28", "decimals": "0", "first": true, "lang": null, "name": "celz:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000022 - Disclosure - LICENSING AGREEMENTS (Details Narrative)", "menuCat": "Details", "order": "22", "role": "http://celz.com/role/LicensingAgreementsDetailsNarrative", "shortName": "LICENSING AGREEMENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2020-12-01to2020-12-28", "decimals": "0", "first": true, "lang": null, "name": "celz:LicenseFees", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "celz:CompanyPaid", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000023 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "23", "role": "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2017-05-17_celz_StemSpinePatentPurchaseMember", "decimals": "0", "lang": null, "name": "celz:CompanyPaid", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000024 - Disclosure - STOCKBASED COMPENSATION (Details)", "menuCat": "Details", "order": "24", "role": "http://celz.com/role/StockbasedCompensationDetails", "shortName": "STOCKBASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30_celz_WarrantssMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_OptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000025 - Disclosure - STOCKBASED COMPENSATION (Details 1)", "menuCat": "Details", "order": "25", "role": "http://celz.com/role/StockbasedCompensationDetails1", "shortName": "STOCKBASED COMPENSATION (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31_us-gaap_OptionMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000026 - Disclosure - STOCKBASED COMPENSATION (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://celz.com/role/StockbasedCompensationDetailsNarrative", "shortName": "STOCKBASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30_celz_EmployeeStockOptionssMember", "decimals": null, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000027 - Disclosure - STOCKHOLDERS EQUITY (Details)", "menuCat": "Details", "order": "27", "role": "http://celz.com/role/StockholdersEquityDetails", "shortName": "STOCKHOLDERS EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "celz:ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "INF", "lang": null, "name": "us-gaap:DebtInstrumentInterestRateDuringPeriod", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "celz:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31_celz_MinimumsssMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000028 - Disclosure - STOCKHOLDERS EQUITY (Details 1)", "menuCat": "Details", "order": "28", "role": "http://celz.com/role/StockholdersEquityDetails1", "shortName": "STOCKHOLDERS EQUITY (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "celz:ScheduleOfWarrantActivityTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2022-12-31_celz_MinimumsssMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-05-01to2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DescriptionOfAmendment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000029 - Disclosure - STOCKHOLDERS EQUITY (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://celz.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-05-01to2022-05-03", "decimals": null, "first": true, "lang": "en-US", "name": "celz:DescriptionOfAmendment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockNoParValue", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-12-01to2022-12-15", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000030 - Disclosure - SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://celz.com/role/SignificantResearchAndDevelopmentPurchasesDetailsNarrative", "shortName": "SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2022-12-01to2022-12-15", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-04-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "5", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "6", "role": "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "AsOf2021-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "7", "role": "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies", "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:LicensingAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000008 - Disclosure - LICENSING AGREEMENTS", "menuCat": "Notes", "order": "8", "role": "http://celz.com/role/LicensingAgreements", "shortName": "LICENSING AGREEMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "celz:LicensingAgreementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "000009 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "9", "role": "http://celz.com/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "celz_10q.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 22, "tag": { "celz_AccumulatedAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Amortization 1]", "verboseLabel": "Amortization" } } }, "localname": "AccumulatedAmortization", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accumulated Amortization" } } }, "localname": "AccumulatedAmortizationAbstract", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "celz_AccumulatedAmortizationAdditionOfNewAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Addition of new assets" } } }, "localname": "AccumulatedAmortizationAdditionOfNewAssets", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationBeginningBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Accumulated Amortization, Beginning Balance]", "periodStartLabel": "Accumulated Amortization, Beginning Balance" } } }, "localname": "AccumulatedAmortizationBeginningBalance", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AccumulatedAmortizationEndingBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Accumulated Amortization, Ending Balance]", "periodEndLabel": "Accumulated Amortization, Ending Balance" } } }, "localname": "AccumulatedAmortizationEndingBalance", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_AgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Agreement Description" } } }, "localname": "AgreementDescription", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_AssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetAbstract", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "stringItemType" }, "celz_BlackScholesMethodMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Black Scholes Method [Member]" } } }, "localname": "BlackScholesMethodMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_BoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Board of Directors [Member]" } } }, "localname": "BoardOfDirectorsMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_CMHMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CMH [Member]" } } }, "localname": "CMHMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Combined offering price of Pre-Funded Warrant and related Common Warrant" } } }, "localname": "CombinedOfferingPriceOfPreFundedWarrantAndRelatedCommonWarrant", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_CommonStockIssue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "common stock Issue" } } }, "localname": "CommonStockIssue", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_CommonStockIssued1": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common Stock Issued" } } }, "localname": "CommonStockIssued1", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for related party patent liabilities, amount" } } }, "localname": "CommonStockIssuedForRelatedPartyPatentLiabilitiesAmount", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_CommonStockIssuedForRelatedPartyPatentLiabilitiesShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for related party patent liabilities, shares" } } }, "localname": "CommonStockIssuedForRelatedPartyPatentLiabilitiesShares", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_CommonWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common warrants exercise price" } } }, "localname": "CommonWarrantsExercisePrice", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_CompanyPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Company paid CMH", "verboseLabel": "Company Paid Cmh" } } }, "localname": "CompanyPaid", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Conversion of management fees and patent liability into common stock" } } }, "localname": "ConversionOfManagementFeesAndPatentLiabilityIntoCommonStock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_DescriptionOfAmendment": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Amendment description" } } }, "localname": "DescriptionOfAmendment", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_DueToRelatedPartyCurrent": { "auth_ref": [], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 11.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Advances from related party" } } }, "localname": "DueToRelatedPartyCurrent", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "celz_EarningsPerShareBasicsAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NET LOSS PER SHARE - BASIC AND DILUTED" } } }, "localname": "EarningsPerShareBasicsAndDiluted", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "celz_EmployeeStockOptionssMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Stock Options [Member]" } } }, "localname": "EmployeeStockOptionssMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_ExpectedAmountOfAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Expected amount of amortization" } } }, "localname": "ExpectedAmountOfAmortization", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ExpectedAnnualAmortizationAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Expected annual amortization amount" } } }, "localname": "ExpectedAnnualAmortizationAmount", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_ExpirationPeriodOfFiniteLivedIntangibleAssets": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Expiration period of finite-lived intangible assets" } } }, "localname": "ExpirationPeriodOfFiniteLivedIntangibleAssets", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_FutureEstimatedStockBasedCompensation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Future estimated stock-based compensation" } } }, "localname": "FutureEstimatedStockBasedCompensation", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_InitialPaymentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Initial payment amount" } } }, "localname": "InitialPaymentAmount", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/SignificantResearchAndDevelopmentPurchasesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_InitialPaymentsToAcquireIntangibleAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial payment" } } }, "localname": "InitialPaymentsToAcquireIntangibleAssets", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_IssuedWarrantToPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issued warrant to purchase shares of common stock" } } }, "localname": "IssuedWarrantToPurchaseSharesOfCommonStock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_JadiCellLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jadi Cell License Agreement [Member]" } } }, "localname": "JadiCellLicenseAgreementMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_JadiCellMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Jadi Cell [Member]" } } }, "localname": "JadiCellMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_LicenseAgreementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License agreement description" } } }, "localname": "LicenseAgreementDescription", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_LicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "License Agreement" } } }, "localname": "LicenseAgreementMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_LicenseFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "License fees" } } }, "localname": "LicenseFees", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_Licensefee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "License Fee" } } }, "localname": "Licensefee", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_LicensingAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "[Beginning Balance]", "periodStartLabel": "Beginning Balance" } } }, "localname": "LicensingAgreements", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_LicensingAgreementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LICENSING AGREEMENTS" } } }, "localname": "LicensingAgreementsAbstract", "nsuri": "http://celz.com/20230630", "xbrltype": "stringItemType" }, "celz_LicensingAgreementsBeginningBalance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Ending balance]", "periodEndLabel": "Ending balance" } } }, "localname": "LicensingAgreementsBeginningBalance", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "celz_LicensingAgreementsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[LICENSING AGREEMENTS]", "verboseLabel": "LICENSING AGREEMENTS" } } }, "localname": "LicensingAgreementsDisclosureTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreements" ], "xbrltype": "textBlockItemType" }, "celz_MinimumsssMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants [Member]" } } }, "localname": "MinimumsssMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "domainItemType" }, "celz_NoOfShareExchange": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "No of share Exchange" } } }, "localname": "NoOfShareExchange", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_NonroyaltySubleaseIncomePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-royalty sublease income percentage" } } }, "localname": "NonroyaltySubleaseIncomePercentage", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_NumberOfShareIssuanceOfCommonStockToJadiCell": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of share issuance of common stock to Jadi Cell" } } }, "localname": "NumberOfShareIssuanceOfCommonStockToJadiCell", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_ObligationOfTheInitialPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "obligation of the initial payment", "verboseLabel": "Obligation Of The Initial Payment" } } }, "localname": "ObligationOfTheInitialPayment", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_OptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Options [Member]" } } }, "localname": "OptionsMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_PaidPlacementAgentFee": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Paid placement agent fee" } } }, "localname": "PaidPlacementAgentFee", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsInTheEventOfCommercializationOfTechnology": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments in the event of commercialization of technology" } } }, "localname": "PaymentsInTheEventOfCommercializationOfTechnology", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponCompletionOfIrbClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments upon completion of the IRB clinical trial" } } }, "localname": "PaymentsUponCompletionOfIrbClinicalTrial", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponDosingOfFirstPatientInPhase12ClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments upon dosing of the first patient in a Phase 1-2 clinical trial" } } }, "localname": "PaymentsUponDosingOfFirstPatientInPhase12ClinicalTrial", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments upon dosing of the first patient in Phase 3 clinical trial" } } }, "localname": "PaymentsUponDosingOfFirstPatientInPhase3ClinicalTrial", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponFilingIndWithFda": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments upon filing an IND with the FDA" } } }, "localname": "PaymentsUponFilingIndWithFda", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PaymentsUponSigningAgreementWithUniversityForInitiationOfIrbClinicalTrial": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payments upon signing agreement with university for the initiation of an IRB clinical trial" } } }, "localname": "PaymentsUponSigningAgreementWithUniversityForInitiationOfIrbClinicalTrial", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_PercentageOfDiscountOnTheBasisOfRecentTradingPrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Percentage of discount on the basis of recent trading price" } } }, "localname": "PercentageOfDiscountOnTheBasisOfRecentTradingPrice", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_PreFundedWarrantsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Pre-Funded Warrants Exercise price" } } }, "localname": "PreFundedWarrantsExercisePrice", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_PrivateOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Private Offering [Member]" } } }, "localname": "PrivateOfferingMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_ProceedsFromIssuanceOfCommonStockAndWarrants": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Proceeds from sale of common stock and warrants, net of issuance costs" } } }, "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_ProceedsFromRedemptionsOfCertificatesOfDeposit": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Redemptions of certificates of deposit" } } }, "localname": "ProceedsFromRedemptionsOfCertificatesOfDeposit", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "celz_PurchaseOfPreFundedWarrantAndRelatedCommonWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of Pre-Funded Warrant and related Common Warrant" } } }, "localname": "PurchaseOfPreFundedWarrantAndRelatedCommonWarrant", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_PurchaseOfWarrantsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Purchase of warrants shares" } } }, "localname": "PurchaseOfWarrantsShares", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_RemainingPortionOfObligationPaidInCash": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Remaining portion of obligation paid in cash" } } }, "localname": "RemainingPortionOfObligationPaidInCash", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_RepurchaseOfStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Repurchase of common stock" } } }, "localname": "RepurchaseOfStock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_RestrictedCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Restricted common stock" } } }, "localname": "RestrictedCommonStock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_RisksAndUncertaintiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Risks And Uncertainties" } } }, "localname": "RisksAndUncertaintiesPolicyTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "celz_RothCapitalPartnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Roth Capital Partners [Member]" } } }, "localname": "RothCapitalPartnersMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_RoyaltyPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Royalty payment percentage" } } }, "localname": "RoyaltyPaymentPercentage", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "percentItemType" }, "celz_ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assumption used in calculation of fair value of options" } } }, "localname": "ScheduleOfAssumptionUsedInCalculationOfFairValueOfOptionsTableTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "celz_ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of assumptions used in calcutation of fair value of warrants" } } }, "localname": "ScheduleOfAssumptionsUsedInCalcutationOfFairValueOfWarrantsTableTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "celz_ScheduleOfLicensingAgreementsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of rental expense from operating leases for each period for which an income statement is presented with separate amounts for minimum rentals, contingent rentals, and sublease rentals. Rental payments under leases with terms of a month", "label": "Schedule Of Licensing Agreements" } } }, "localname": "ScheduleOfLicensingAgreementsTableTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsTables" ], "xbrltype": "textBlockItemType" }, "celz_ScheduleOfWarrantActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrant activity" } } }, "localname": "ScheduleOfWarrantActivityTableTextBlock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityTables" ], "xbrltype": "textBlockItemType" }, "celz_SeriesAPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series A, Preferred Stock" } } }, "localname": "SeriesAPreferredStocksMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SeriesBPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series B, Preferred Stock" } } }, "localname": "SeriesBPreferredStocksMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SeriesCPreferredStocksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Series C, Preferred Stock" } } }, "localname": "SeriesCPreferredStocksMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "celz_SharePriceForTwoOrMoreConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share price for two or more consecutive trading days" } } }, "localname": "SharePriceForTwoOrMoreConsecutiveTradingDays", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "celz_SignificantResearchAndDevelopmentPurchaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE" } } }, "localname": "SignificantResearchAndDevelopmentPurchaseAbstract", "nsuri": "http://celz.com/20230630", "xbrltype": "stringItemType" }, "celz_StemSpineMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StemSpine LLC [Member]" } } }, "localname": "StemSpineMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_StemSpinePatentPurchaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "StemSpine Patent Purchase [Member]" } } }, "localname": "StemSpinePatentPurchaseMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_StockIssuedDuringPeriodSharesCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Issuance of common stock and accompanying warrants, net of issuance costs, shares" } } }, "localname": "StockIssuedDuringPeriodSharesCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_StockIssuedDuringPeriodSharesStockWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercise, shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockWarrantsExercised", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "celz_StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "[Issuance of common stock and accompanying warrants, net of issuance costs, amount]", "verboseLabel": "Issuance of common stock and accompanying warrants, net of issuance costs, amount" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsAmount", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Issuance of common stock and accompanying warrants, net of issuance costs, amount" } } }, "localname": "StockIssuedDuringPeriodValueCommonStockAndAccompanyingWarrantsNetOfIssuanceCostsShares", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_StockIssuedDuringPeriodValueReverseStockSplits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Round-up shares issued in reverse stock split, amount" } } }, "localname": "StockIssuedDuringPeriodValueReverseStockSplits", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_StockIssuedDuringPeriodValueStockWarrantsExercised": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Common stock issued for warrant exercise, amount" } } }, "localname": "StockIssuedDuringPeriodValueStockWarrantsExercised", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "celz_ValueOfOptionsVest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Options vested, value" } } }, "localname": "ValueOfOptionsVest", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "celz_WarrantExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrant exercise price" } } }, "localname": "WarrantExercisePrice", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "celz_WarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "[Warrants [Member]]", "verboseLabel": "Warrants [Member]" } } }, "localname": "WarrantsMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "celz_WarrantsPurchaseSharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants to purchase shares of common stock" } } }, "localname": "WarrantsPurchaseSharesOfCommonStock", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "celz_WarrantssMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Option Warrant [Member]" } } }, "localname": "WarrantssMember", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "domainItemType" }, "celz_WeightedAverageLifeRemainingOutstandingBeginning": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Life Remaining, Outstanding beginning" } } }, "localname": "WeightedAverageLifeRemainingOutstandingBeginning", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "celz_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted", "nsuri": "http://celz.com/20230630", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r446" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r447" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://celz.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r14", "r430" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 9.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r16" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 10.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r44", "r430", "r508" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 14.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r246", "r247", "r248", "r356", "r463", "r464", "r465", "r501", "r509" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r3", "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "[Amortization]", "verboseLabel": "Amortization" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfIntangibleAssets": { "auth_ref": [ "r3", "r33", "r34" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Amortization of patent costs", "terseLabel": "Amortization expenses", "verboseLabel": "Amortization" } } }, "localname": "AmortizationOfIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive Securities Excluded From Computation Of Earning Per Share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r71", "r94", "r112", "r128", "r134", "r138", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r256", "r260", "r272", "r335", "r378", "r430", "r441", "r471", "r472", "r504" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets]", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r89", "r97", "r112", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r256", "r260", "r272", "r430", "r471", "r472", "r504" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "[Assets, Current]", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT ASSETS" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis Of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r22", "r92", "r419" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r22", "r55", "r109" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents]", "periodEndLabel": "ENDING CASH BALANCE", "periodStartLabel": "BEGINNING CASH BALANCE" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r1", "r55" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "[Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect]", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CertificatesOfDepositAtCarryingValue": { "auth_ref": [ "r455" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A savings certificate entitling the Entity (that is, bearer) to receive interest at an established maturity date, based upon a fixed interest rate. A certificate of deposit may be issued in any denomination. Certificates of deposit are generally issued by commercial banks and, therefore, insured by the FDIC (up to the prescribed limit). Certificates of deposit generally restrict holders from withdrawing funds on demand without the incurrence of penalties. Generally, only certificates of deposit with original maturities of three months or less qualify as cash equivalents. Original maturity means original maturity to the entity holding the investment. As a related example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.", "label": "Certificates of deposit" } } }, "localname": "CertificatesOfDepositAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r40", "r336", "r365" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r20" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Sale of shares of common stock" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r431", "r432", "r433", "r435", "r436", "r437", "r438", "r463", "r464", "r501", "r507", "r509" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockNoParValue": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Face amount per share of no-par value common stock.", "label": "Common Stock, Shares Par Value" } } }, "localname": "CommonStockNoParValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r43", "r366" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares Issued", "verboseLabel": "Common Stock Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r6", "r43", "r366", "r384", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r43", "r337", "r430" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 13.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,127 and 1,407,625 issued and 1,431,126 and 1,407,624 outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r41", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risks" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r37", "r421" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Organization" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockDescription": { "auth_ref": [ "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock description" } } }, "localname": "ConversionOfStockDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockSharesIssued1": { "auth_ref": [ "r25", "r26", "r27" ], "lang": { "en-us": { "role": { "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Additional stock issued" } } }, "localname": "ConversionOfStockSharesIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r52", "r112", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r272", "r471" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1": { "auth_ref": [ "r25", "r27" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Stock option, Issued", "verboseLabel": "Stock option, Issued" } } }, "localname": "DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DEBT" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r63", "r110", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r205", "r206", "r208" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "verboseLabel": "DEBT" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/DEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r18", "r38", "r204" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "[Debt Instrument, Interest Rate During Period]", "verboseLabel": "Risk-free interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepositLiabilitiesDisclosuresTextBlock": { "auth_ref": [ "r5", "r39", "r85", "r86" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for deposit liabilities including data and tables. It may include a description of the entity's deposit liabilities, the aggregate amount of time deposits (including certificates of deposit) in denominations of $100,000 or more at the balance sheet date; the aggregate amount of any demand deposits that have been reclassified as loan balances, such as overdrafts, at the balance sheet date; deposits that are received on terms other than those in the normal course of business, the amount of accrued interest on deposit liabilities; securities, mortgage loans or other financial instruments that serve as collateral for deposits; for time deposits having a remaining term of more than one year, the aggregate amount of maturities for each of the five years following the balance sheet date; and the weighted average interest rate for all deposit liabilities held by the entity.", "label": "Deposit Liabilities Disclosures [Text Block]", "verboseLabel": "DERIVATIVE LIABILITIES" } } }, "localname": "DepositLiabilitiesDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/DerivativeLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DERIVATIVE LIABILITIES" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r232", "r233", "r243", "r244", "r245", "r426" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "verboseLabel": "STOCKBASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKBASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r28", "r29" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Basic and Diluted Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "auth_ref": [ "r499", "r500" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "[Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent]", "verboseLabel": "Expected volatility" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS EQUITY" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r6", "r87", "r100", "r101", "r102", "r113", "r114", "r115", "r117", "r122", "r124", "r127", "r174", "r175", "r222", "r246", "r247", "r248", "r252", "r253", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r345", "r346", "r347", "r356", "r406" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r4", "r13" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r176", "r177", "r178", "r179", "r180", "r181", "r182", "r183", "r207", "r220", "r268", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r343", "r425", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument Axis" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r62", "r320" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Licenses, net of amortization" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r51", "r112", "r128", "r133", "r137", "r139", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r272", "r424", "r471" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "[Gross Profit]", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r0", "r49", "r73", "r128", "r133", "r137", "r139", "r333", "r340", "r424" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 12.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "[Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest]", "totalLabel": "LOSS BEFORE PROVISION FOR INCOME TAXES" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r76", "r83", "r123", "r124", "r131", "r251", "r254", "r344" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 13.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r24" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Cash payments for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "[Increase (Decrease) in Accounts Payable]", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "[Increase (Decrease) in Accounts Receivable]", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "[Increase (Decrease) in Accrued Liabilities]", "verboseLabel": "Accrued expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "[Increase (Decrease) in Inventories]", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "[Increase (Decrease) in Prepaid Expense and Other Assets]", "negatedLabel": "Prepaids and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeOther": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest income earned from interest bearing assets classified as other.", "label": "Interest income" } } }, "localname": "InterestIncomeOther", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r104", "r107", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Cash payments for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r96", "r420", "r430" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryPolicyTextBlock": { "auth_ref": [ "r77", "r91", "r95", "r184", "r185", "r186", "r318", "r422" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.", "label": "Inventories" } } }, "localname": "InventoryPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r15", "r112", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r257", "r260", "r261", "r272", "r364", "r423", "r441", "r471", "r504", "r505" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 16.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "[Liabilities]", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r48", "r72", "r339", "r430", "r462", "r470", "r502" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "[Liabilities and Equity]", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r17", "r90", "r112", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r257", "r260", "r261", "r272", "r430", "r471", "r504", "r505" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 12.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "[Liabilities, Current]", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CURRENT LIABILITIES" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermPurchaseCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.", "label": "Long-term Purchase Commitment, Amount" } } }, "localname": "LongTermPurchaseCommitmentAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 16.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "[Net Cash Provided by (Used in) Financing Activities]", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r106" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "[Net Cash Provided by (Used in) Investing Activities]", "totalLabel": "Net cash provided by investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r55", "r56", "r57" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "[Net Cash Provided by (Used in) Operating Activities]", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r50", "r57", "r74", "r88", "r98", "r99", "r102", "r112", "r116", "r118", "r119", "r120", "r121", "r123", "r124", "r125", "r128", "r133", "r137", "r139", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r271", "r272", "r342", "r386", "r404", "r405", "r424", "r439", "r471" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "[Net Income (Loss) Attributable to Parent]", "totalLabel": "NET LOSS", "verboseLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NON-CASH INVESTING AND FINANCING ACTIVITIES:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 11.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "[Nonoperating Income (Expense)]", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER INCOME/(EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "[Operating Expenses]", "totalLabel": "TOTAL EXPENSES" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OPERATING EXPENSES" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r128", "r133", "r137", "r139", "r424" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 10.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "[Operating Income (Loss)]", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r461" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "[Operating Lease, Right-of-Use Asset, Amortization Expense]", "verboseLabel": "Amortization expenses" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OptionMember": { "auth_ref": [ "r69", "r374", "r379", "r394", "r400", "r414", "r415", "r416", "r431", "r432" ], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific commodity, or financial or equity instrument, at a specified price during a specified period (an American option) or at a specified date (a European option) which were purchased or otherwise acquired, excluding options written (for which a premium was received).", "label": "Option [Member]" } } }, "localname": "OptionMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r58", "r59", "r60", "r68" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "verboseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r70", "r93", "r334", "r441" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OTHER ASSETS" } } }, "localname": "OtherAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIntangibleAssetsNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated amortization of finite-lived and indefinite-lived intangible assets classified as other.", "label": "Carrying value of patent" } } }, "localname": "OtherIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForDepositsOnRealEstateAcquisitions": { "auth_ref": [ "r459" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow related to amounts given in advance to show or confirm an intention to complete an acquisition of land, buildings, other structures, or any item classified as real estate.", "label": "[Payments for Deposits on Real Estate Acquisitions]", "negatedLabel": "Investments in certificates of deposit" } } }, "localname": "PaymentsForDepositsOnRealEstateAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name Axis" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r457" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaids and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromWarrantExercises": { "auth_ref": [ "r460" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.", "label": "Proceeds from exercise of warrants" } } }, "localname": "ProceedsFromWarrantExercises", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r88", "r98", "r99", "r105", "r112", "r116", "r123", "r124", "r128", "r133", "r137", "r139", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r255", "r258", "r259", "r271", "r272", "r333", "r341", "r355", "r386", "r404", "r405", "r424", "r428", "r429", "r440", "r458", "r471" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "[Net Income (Loss), Including Portion Attributable to Noncontrolling Interest]", "negatedLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r231", "r283", "r284", "r359", "r360", "r361", "r362", "r363", "r383", "r385", "r413" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r283", "r284", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party." } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r231", "r283", "r284", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r359", "r360", "r361", "r362", "r363", "r383", "r385", "r413", "r503" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party Axis" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r280", "r281", "r282", "r284", "r285", "r352", "r353", "r354", "r389", "r390", "r391", "r410", "r412" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "verboseLabel": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)" } } }, "localname": "ResearchAndDevelopmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r42", "r249", "r506" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "verboseLabel": "Research and development expenses" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/SignificantResearchAndDevelopmentPurchasesDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock": { "auth_ref": [ "r75", "r250" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.", "label": "Research, Development, and Computer Software Disclosure [Text Block]", "verboseLabel": "SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASE" } } }, "localname": "ResearchDevelopmentAndComputerSoftwareDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/SignificantResearchAndDevelopmentPurchase" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r45", "r65", "r338", "r348", "r349", "r351", "r367", "r430" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 15.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r87", "r113", "r114", "r115", "r117", "r122", "r124", "r174", "r175", "r246", "r247", "r248", "r252", "r253", "r262", "r264", "r265", "r267", "r270", "r345", "r347", "r356", "r509" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r84", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r418" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r103", "r112", "r129", "r130", "r132", "r135", "r136", "r140", "r141", "r142", "r173", "r187", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r272", "r333", "r471" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r11", "r12", "r36" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r2" ], "calculation": { "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Stock-based compensation", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Life Remaining, Outstanding ending" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Annual dividend yield", "verboseLabel": "Annual dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r240" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Number of non-option equity instruments exercised by participants.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised]", "negatedLabel": "Warrants, Exercises" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Net number of non-option equity instruments granted to participants.", "label": "Warrants, Issuances" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": { "auth_ref": [ "r7", "r8" ], "lang": { "en-us": { "role": { "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number]", "periodEndLabel": "Warrants, Outstanding Ending Balance", "periodStartLabel": "Warrants, Outstanding Beginning Balance" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Number of shares authorized for issuance under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number]", "periodEndLabel": "Stock option, Outstanding at the end", "periodStartLabel": "Stock option, Outstanding at the begining" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r234", "r235" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "[Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price]", "periodEndLabel": "Weighted Average Exercise Price, Outstanding ending", "periodStartLabel": "Weighted Average Exercise Price, Outstanding beginning" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Common stock price", "terseLabel": "Common stock price", "verboseLabel": "Common stock price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r239" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected life (years)", "verboseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockholdersEquityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted Average Life Remaining, Outstanding Ending" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r238" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Life Remaining, Outstanding Beginning" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Weighted Average Life Remaining, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Stock option, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "sharesItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant-date fair value of options vested.", "label": "Weighted Average Exercise Price, Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesIssued": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.", "label": "[Shares, Issued]", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r6", "r21", "r87", "r100", "r101", "r102", "r113", "r114", "r115", "r117", "r122", "r124", "r127", "r174", "r175", "r222", "r246", "r247", "r248", "r252", "r253", "r262", "r263", "r264", "r265", "r266", "r267", "r270", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r345", "r346", "r347", "r356", "r406" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r113", "r114", "r115", "r127", "r319", "r350", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r366", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r380", "r381", "r382", "r383", "r385", "r387", "r388", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r434" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails1", "http://celz.com/role/StockholdersEquityDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONDENSED CONSOLIDATED BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r113", "r114", "r115", "r127", "r319", "r350", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r366", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r379", "r380", "r381", "r382", "r383", "r385", "r387", "r388", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402", "r403", "r406", "r434" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative", "http://celz.com/role/RelatedPartyTransactionsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetails1", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails1", "http://celz.com/role/StockholdersEquityDetailsNarrative", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split.", "label": "Round-up shares issued in reverse stock split, shares" } } }, "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r43", "r46", "r47", "r61", "r368", "r384", "r407", "r408", "r430", "r441", "r462", "r470", "r502", "r509" ], "calculation": { "http://celz.com/role/CondensedConsolidatedBalanceSheets": { "order": 17.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "[Stockholders' Equity Attributable to Parent]", "periodEndLabel": "Balance, amount", "periodStartLabel": "Balance, amount", "totalLabel": "TOTAL STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets", "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/CondensedConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r64", "r111", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r221", "r222", "r269", "r409", "r411", "r417" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "STOCKHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Reverse split description" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by business subsegments.", "label": "Subsegments Axis" } } }, "localname": "SubsegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_SubsegmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SubsegmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails", "http://celz.com/role/StockbasedCompensationDetailsNarrative", "http://celz.com/role/StockholdersEquityDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r286", "r287" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "verboseLabel": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock Axis" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SUPPLEMENTAL CASH FLOW INFORMATION:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/UnauditedCondensedConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TimeDepositsAtOrAboveFDICInsuranceLimit": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of time deposit liabilities, including certificates of deposit, in denominations that meet or exceed the Federal Deposit Insurance Corporation (FDIC) insurance limit.", "label": "FDIC insured amount" } } }, "localname": "TimeDepositsAtOrAboveFDICInsuranceLimit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r207", "r220", "r268", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r343", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r466", "r467", "r468", "r469" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/LicensingAgreementsDetailsNarrative", "http://celz.com/role/StockbasedCompensationDetails1" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r30", "r31", "r32", "r78", "r79", "r81", "r82" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use Of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://celz.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "https://asc.fasb.org//330/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "330", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org//718/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "330", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.12)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r442": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r446": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r447": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r448": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(26)(c))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org//250/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "83", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480647/815-10-15-83", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "730", "Topic": "985", "URI": "https://asc.fasb.org//985-730/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(e)", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Regulation S-K (SK)", "Number": "229", "Publisher": "SEC", "Section": "1406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 50 0001477932-23-005935-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-005935-xbrl.zip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�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
E]E>#,Q,BYH=&WM6F%S MXC@2_2NZ7,U64@4)A$WM%K!4D4!FN$K"'&&J9N_+E;!EK(ML>24;PO[Z>RT; M< *3S22+PFVI.Z6]%Z_EJ =II'JM$/!_4X[E:D2'4^H/_\M;AOUXT,T MMH_RM^V_5:L][661B%/F&<%3X;/,RGC*^KWWW=$EMZDPU6JG?90;FVA_P6RZ M4.*WO7'_\[C:O1B\OVJR_V0VE<&BQ2E*4R$I;%8LZ,CGC<8I?= MT?O!5?6B?XXNO[Q;O1@-WG]P;_8Z[61IG0Q5KP?_ZN?6(Z#^Z+N'\FET_:E[-6;C(:O_RCX=7A^>';+K_IE;FGKC MI%;YWB%UKUFW-_PX[O=8.;IE3(W:\3-LV?A#GUUW1Z?=J_YU=?CYHO\[ZYZ- M$0@[KM7^/VBR]C*HL)Z.N?)93WHWPE@=5Y@G##6S-.1I\WO.,^43)9:>)MKX M2++M@'K6B-;84-8N^0!=K J%C: M9"+VX>8?62S W0KXKXN1%URBTV&(B)%NPFUG,E M_*FHY, JX.1K,JA10<$-ES'C\8)E<6HRV@?45*Z\ LXXB_!D)! 6< ^O#-.1 M1*6D\WX;'6+A"6NY65"7B-$A[V538MW/H*!2T7[0SZH@R<-:CITBS$"Y LIL@-.UCFEA^+,ID M45Z&-]@_(>P;/RSL!0MD#& 11M= J@#SZ(YF4VJ7,=(E$"UA1\:>RBA7 JPE MU%0 =$FI.0'6B"9$'Z76/"@@:.^Y!M5\288KU"-3Z #P:R#4N;,N'H_;D 5* MS^V2&49,):H9#D><7N9Q(\I*">"V',P;PG>#$^?&^'C.W#XZ>^_'M=_:=D" MPT4]2(E0!X'$X[X]<%@9,&Z$0R50)FE'J"00EG9'VI!&4+<(.D!:0,^^M)[2 M-L,X4@BC50[/Q&A/^'AMV3[0Z O .R=(_]8+>3P5K(OD.\H4>M0;O%H_V1=Y M%/43/W_*'R45]'%."[+/*$.7V)+CEV)YC*.J\Q3<\13 T[+V*9,(/:CB:KY* M:CP%#];3V.#"KBG(#YZ9@CUAT00DNK+DKVE2H8K)XYE]_! J728"D"\\Y<60 MSK#+&;+]3%JG(>@E8F>'3H!K]2DKF!&*.PX5U=":!I5"W:A10HD0B]5*^NXZ MS683*WW)C:0)R+QF(DE)B6 M"V)=CV%$7MV5BU)\F@CJ""W#>.&_3O5ZX12=_%@4?;3.;##U\0KU:,*"Y#/I M$P^YU;&#%[?@,)UZB)S<^$NB@+J23Z22Z8(JP6UN*6TX3CFZY(R_T[5T:G** M?UM,*,E, KI:5[EZ'I#M G#GIZF(49 JL!8M(J%T0%UP-LR9B;0A$XCN&S=? M(#>]Y^9F?\95YC2&@"N" .]!9TB@[^^;&"3Y?G491>1KP3B:9'Q-S:]/#;YS\VF7@[4 M3<#3;5YQ2G(M6UGUH+XAUY?TC0I,[7F9(5B7JKDM5B-M4[RG+VQ@R]+5]/+B M>?\+0P+P$\ISKW<1N ?6N(M(NJ.,LY4 'N11A=RN2E_2+,=GX3LQ=^M1".V" M*7DC5'$K>:]_Y9N6J*S%KY?#.^+6R8N]:W'?YOA+9E;6:9]4J,R.M0(0OK^B M3MTXS*VBXSC0I=K856GH7L!D%,DT%>(!C9UH%)_4[DO$YXSL@T.)^[;1TG\Z M5BZ)+_[(),)W),]BS]U?'KS=J+Q $7OV&Y6NPD$%C1(\HOLYNNKSI #JB[)N M=;,Q%_R&ZK3\X.(J-7?DI6\6+2H%&T68;I8*3>90J"W?N'P>D7DA7/HV:\\NJCW H-D7P&BA9,H M<,)]/5J0IY*72S*>:3431*J83XMO>4VA:B)*E%X(.)Z'.M:H-(W%Y1E MVAV^/I"?U#;0-]%IJJ,G 6 /N]QDW6R*^;)Z/?]1QP-4:.PRF--%DVWU?3H< M]?JCZNEP/!Y>8F.36^;NG(LU;ISL,JJVB#I']FCCAU3M(S0\L%3UXYVD)P?\ M!_&SFY2XVT2[H_RZN6<[G=';WGR%Q[-0BH"=KY+\,#\/O6W1C[-%^Q_S6WOL MSL8^'7R/C=HB\/^[=?I=?^>_4$L#!!0 ( +&%"UE]E>#,R,2YH=&WM6&%OXD80_2M3JIP2"8,-1WMG?$B$F,15$N[ M:=-^J19[C;>U=]W=]07?K^^L@00E7*IK0WIJ(R$+[Z[GS9MY,V/P4IUG R^E M)!YXFNF,#B*:??J5+KL=IX6;7GNUZGUC627!ZZ<)OI=(LJ?HPGER&+CAVH4&S MG"K@] :DR GOP\5P>AI<6N?^&(]\?W"[, U.S^J5QL K-M:-(6L6_.*OK*TL M6^/A17#^L_LYVR[8Q;(/FBZU13*VX*YDBU3WT;#24O#%P+\^"XZ#$+J=EN.U MUXM>NQC DT-O8M(8O.)S5?3W@Q)AZJC<8CCRIV$P#D;#,)A<-7+5FK5$+9OZH#HO3[=G_ MB?3?H00<(L$YC303'&Z83D&G3,&'DD@,35;!E!9":A )C$RILX\4+FC,(I)! M2*.4BTPL*C@368P-0#4AX%$+#G5*X=6W;SH=NS\2>4%X5=\Y_2- G+&0.1*P M/D B))BS!95,Q$!Y3.,5\Q]*3J%K-Z%C=[I-( H2EF&C6?M(84:C4C+-D#+A M,?C+*"5\00'QGU-5!S"OX':N$^T^YQ*U62>T0W27,@8!X$J2(01=.U^(KBV%/M$W1KYAL4ZQ:_V00-# MEF4%B8V(WC7LAC$E-W92:OJQZ_2*9;T1;S96!EX?]!O;!.^AU+<)R5E6N??9 MY40N&'=M8_B.!@ZZ>#?.1Y-8E/XZ!EH43P+MM';"/B':CL1M.S KHW1'S?]5 MI<*](DW*#)^.L PR4Y:WI2KI'R63U+PP*"-.M>XW3O>08$.0X/0.XZ-;0=\5 M]FU1KU7MO.V^[IMROXT77J2Y&-V]J/RK5GGGWU9YB.)B'(6_OTS:/YH*W:.UZB MO#9N/1(RI[.7/E<7P*,ZVD]OW6_'WE.CWI6UO7)ZR%!V^ MEPPG>H&C^4&>CIXC43M&_3^W;O[&&_P)4$L#!!0 ( +&%"U>:_9(P"P0 M !@4 . 8V5L>E]E>#,R,BYH=&WM6/UOVS80_5=N'E(D@&5+B(;%36P&Z_3+0$F5QE4B5I!J[?_V.\D>,) W0+0J*K4!@R"3]WKV[=T<[ M?JKSK.>GE,0]7S.=T5Y$LR]_TE7'=5NXZ;-Z?71&EJ;2LGM_>@"U$O :EUQE]UPA''T*K?QF<3SSXJU2:)>LNC*>3 MT /'+C1HEE,%G-Z"%#GA7;CJS\Z#B74Y&N.17X_V"[/@_*)::?3\8H=N@*QY M\,=H@[9!ML;]J^#R=^]KV![8Q:H+FJZT13*VY)YDRU1W$5AI*?BR-_IP$9P% M(73(+573K88FP=%0>*!R,9F$P#@;],)A.8#JN M6>4#_NM9,!D$U_U+& >3/C[BTW2, 8UF+Q[*S6Q^TY^$$$[!>0,WK7EKT(+Y M:%"EQNFN=T M3P!YQD+F*,!Z#XF08,X65#(1 ^4QC3?*?RLYA8[=!-=V.TT@"A*6X;#9QDAA M3J-2,LU0,N$QC%912OB2 O+E3"FC!__,R1BG%*144A1Q&-E]D;L04403AH*3 M+(8ABSY2J01OPB!E-($QXX1'#.5/DX1%5)K4&-"MSB;@FLDN:%&M+ZBJTI>O MX2,7MZAA29M0E%*5!(#:4NP+]2KF M6Q;K%!_MHP:F+,L*$AL+O6O8#0,E=S@I-1/9,\GTUAT?C;'&A1/ NUTWJ4MB:V>1FE MC[3W/VK*I,P0(D+C9Z8-]ZTIZ:>226J^)"AC1[6=+T[GF. D."<'LPO? M-?*^B;<^=MYV7G=->^\SA"_2O!BG_?#U=^UKMW9?/U*XPP!"-!?CZ.:<5/;# MFTX3QG&B,@[J.?N ,(-12*J,Y9L&GV09("]^%*\*W"BP!U2SPDOV5PA&%+,J M-G.%X:DRVW2,0,XJ:/5M-^__KT].[0<&7@BM1?XL'AYB!3WHETO4"XZS*?@3 MW=2I,YBSM0=/]//9=#8)OI\2'5]+ MAL4IL#H/ZG3R$H5ZY)K_]^CF'W>]OP%02P$"% ,4 " "QA0M7.EZ,=ET/ M !)DP $0 @ $ 8V5L>BTR,#(S,#8S,"YXP %0 @ &,#P 8V5L M>BTR,#(S,#8S,%]C86PN>&UL4$L! A0#% @ L84+5UW4YK\8%P 6%T! M !4 ( !=1L &-E;'HM,C R,S V,S!?9&5F+GAM;%!+ 0(4 M Q0 ( +&%"U=>.R.$HS\ -XI P 5 " < R !C96QZ M+3(P,C,P-C,P7VQA8BYX;6Q02P$"% ,4 " "QA0M7TU QA)DO #;@P( M%0 @ &6<@ 8V5L>BTR,#(S,#8S,%]P&UL4$L! A0# M% @ L84+5T+#'.N\LP N;8* P ( !8J( &-E;'I? M,3!Q+FAT;5!+ 0(4 Q0 ( +&%"U=<;%"[%6P ,5_ 0 M " 4A6 0!C96QZ7S$P<6EM9S(N:G!G4$L! A0#% @ L84+5Q!(4/2V M!P IS X ( !B\(! &-E;'I?97@S,3$N:'1M4$L! A0# M% @ L84+5YW*W5ZE!P -S X ( !;

Cover - shares	6 Months Ended
Cover - shares	Jun. 30, 2023	Aug. 11, 2023
Cover [Abstract]
Entity Registrant Name	CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	0001187953
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Jun. 30, 2023
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2023
Entity Common Stock Shares Outstanding		1,430,530
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	000-53500
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	87-0622284
Entity Address Address Line 1	211 E Osborn Road
Entity Address City Or Town	Phoenix
Entity Address State Or Province	AZ
Entity Address Postal Zip Code	85012
City Area Code	480
Local Phone Number	399-2822
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CELZ
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Jun. 30, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash	$ 3,989,550	$ 8,320,519
Certificates of deposit	9,581,207	10,078,617
Inventory	10,194	10,194
Prepaids and other current assets	153,692	338,120
Total Current Assets	13,734,643	18,747,450
OTHER ASSETS
Other assets	3,281	3,281
Licenses, net of amortization	389,553	435,595
TOTAL ASSETS	14,127,477	19,186,326
CURRENT LIABILITIES
Accounts payable	344,413	3,267,538
Accrued expenses	39,920	39,920
Advances from related party	14,194	14,194
Total Current Liabilities	398,527	3,321,652
TOTAL LIABILITIES	398,527	3,321,652
STOCKHOLDERS' EQUITY
Common stock, $0.001 par value, 5,000,000 and 50,000,000 shares authorized; 1,431,127 and 1,407,625 issued and 1,431,126 and 1,407,624 outstanding at June 30, 2023 and December 31, 2022, respectively	1,431	1,408
Additional paid-in capital	69,693,425	69,675,124
Accumulated deficit	(55,965,906)	(53,811,858)
TOTAL STOCKHOLDERS' EQUITY	13,728,950	15,864,674
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 14,127,477	$ 19,186,326

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jun. 30, 2023	Dec. 31, 2022
CONDENSED CONSOLIDATED BALANCE SHEETS
Common Stock, Shares Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	5,000,000	50,000,000
Common Stock, Shares Issued	1,431,127	1,407,625
Common Stock, Shares Outstanding	1,431,126	1,407,624

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
Revenues	$ 0	$ 0	$ 0	$ 15,000
Cost of revenues	0	0	0	6,791
Gross profit	0	0	0	8,209
OPERATING EXPENSES
Research and development	309,480	659,695	628,509	669,695
Selling, general and administrative	859,537	1,108,428	1,630,557	2,238,485
Amortization of patent costs	23,021	23,021	46,042	46,042
TOTAL EXPENSES	1,192,038	1,791,144	2,305,108	2,954,222
Operating loss	(1,192,038)	(1,791,144)	(2,305,108)	(2,946,013)
OTHER INCOME/(EXPENSE)
Interest income	89,913	0	151,060	0
Total other income (expense)	89,913	0	151,060	0
LOSS BEFORE PROVISION FOR INCOME TAXES	(1,102,125)	(1,791,144)	(2,154,048)	(2,946,013)
Provision for income taxes	0	0	0	0
NET LOSS	$ (1,102,125)	$ (1,791,144)	$ (2,154,048)	$ (2,946,013)
NET LOSS PER SHARE - BASIC AND DILUTED	$ (0.78)	$ (1.99)	$ (1.53)	$ (3.81)
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING - BASIC AND DILUTED	1,409,948	901,125	1,408,793	773,970

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Total	Series B, Preferred Stock	Series C, Preferred Stock	Common Stock	Series A, Preferred Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)
Balance, shares at Dec. 31, 2021				633,886
Balance, amount at Dec. 31, 2021	$ 10,217,740	$ 0	$ 0	$ 634	$ 0	$ 53,884,920	$ (43,667,814)
Issuance of common stock and accompanying warrants, net of issuance costs, shares				299,167
Issuance of common stock and accompanying warrants, net of issuance costs, amount	15,471,775	0	0	$ 299	0	15,471,476	0
Common stock issued for related party patent liabilities, shares				18,182
Common stock issued for related party patent liabilities, amount	250,000	0	0	$ 18	0	249,982	0
Common stock issued for warrant exercise, shares				444,389
Common stock issued for warrant exercise, amount	445	0	0	$ 444	0	1	0
Stock-based compensation	50,422	0	0	0	0	50,422	0
Net loss	(2,946,013)	0	0	$ 0	0	0	(2,946,013)
Balance, shares at Jun. 30, 2022				1,395,624
Balance, amount at Jun. 30, 2022	23,044,369	0	0	$ 1,395	0	69,656,801	(46,613,827)
Balance, shares at Mar. 31, 2022				652,068
Balance, amount at Mar. 31, 2022	9,354,231	0	0	$ 652	0	54,176,262	(44,822,683)
Issuance of common stock and accompanying warrants, net of issuance costs, shares				299,167
Common stock issued for warrant exercise, shares				444,389
Common stock issued for warrant exercise, amount	445	0	0	$ 444	0	1	0
Stock-based compensation	9,062	0	0	0	0	9,062	0
Net loss	(1,791,144)	0	0	0	0	0	(1,791,144)
Issuance of common stock and accompanying warrants, net of issuance costs, amount	15,471,775	0	0	$ 299	0	15,471,476	0
Balance, shares at Jun. 30, 2022				1,395,624
Balance, amount at Jun. 30, 2022	23,044,369	0	0	$ 1,395	0	69,656,801	(46,613,827)
Balance, shares at Dec. 31, 2022				1,407,624
Balance, amount at Dec. 31, 2022	15,864,674	0	0	$ 1,408	0	69,675,124	(53,811,858)
Stock-based compensation	18,324	0	0	0	0	18,324	0
Net loss	(2,154,048)	0	0	$ 0	0	0	(2,154,048)
Round-up shares issued in reverse stock split, shares				23,502
Round-up shares issued in reverse stock split, amount	0	0	0	$ 23	0	(23)	0
Balance, shares at Jun. 30, 2023				1,431,126
Balance, amount at Jun. 30, 2023	13,728,950	0	0	$ 1,431	0	69,693,425	(55,965,906)
Balance, shares at Mar. 31, 2023				1,407,624
Balance, amount at Mar. 31, 2023	14,821,913	0	0	$ 1,408	0	69,684,286	(54,863,781)
Stock-based compensation	9,162	0	0	0	0	9,162	0
Net loss	(1,102,125)	0	0	$ 0	0	0	(1,102,125)
Round-up shares issued in reverse stock split, shares				23,502
Round-up shares issued in reverse stock split, amount	0	0	0	$ 23	0	(23)	0
Balance, shares at Jun. 30, 2023				1,431,126
Balance, amount at Jun. 30, 2023	$ 13,728,950	$ 0	$ 0	$ 1,431	$ 0	$ 69,693,425	$ (55,965,906)

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2023
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Organization	Organization - Creative Medical Technologies Holdings, Inc. (the “Company”) is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company was incorporated on December 3, 1998, in the State of Nevada under the name Jolley Marketing, Inc. On May 18, 2016, the Company closed a transaction which was accounted for as a recapitalization, reverse merger, under which Creative Medical Technologies, Inc., a Nevada corporation (“CMT”) became the Company’s wholly owned subsidiary, and Creative Medical Health, Inc. (“CMH”), which was CMT’s sole stockholder prior to the merger, became the Company’s principal stockholder. In connection with this merger, the Company changed its name to Creative Medical Technologies Holdings, Inc. to reflect its current business. CMT was originally created on December 30, 2015 (“Inception”), as the urological arm of CMH to monetize a patent and related intellectual property related to the treatment of erectile dysfunction (“ED”), which it acquired from CMH in February 2016. Subsequently, the Company has expanded its development and acquisition of intellectual property beyond urology to include therapeutic treatments utilizing “re-programmed” stem cells, and the treatment of neurologic disorders, lower back pain, type I diabetes, and heart, liver, kidney, and other diseases using various types of stem cells through our ImmCelz, Inc., StemSpine, Inc. and AlloCelz LLC subsidiaries. However, neither ImmCelz Inc., StemSpine Inc. nor AlloCelz LLC have commenced commercial activities. The Company currently conducts substantially all of its commercial operations through CMT, which markets and sells the Company’s CaverStem^® and FemCelz^®disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. In 2020, through the Company’s ImmCelz Inc. subsidiary, the Company began developing treatments that utilize a patient’s own extracted immune cells that are then “reprogrammed” by culturing them outside the patient’s body with optimized stem cells. The immune cells are then re-injected into the patient from whom they were extracted. The Company believes this process endows the immune cells with regenerative properties that may be suitable for the treatment of multiple indications. In contrast to other stem cell-based approaches, the immune cells are significantly smaller in size than stem cells and are believed to more effectively penetrate areas of the damaged tissues and induce regeneration.
Use Of Estimates	*Use of Estimates –*The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Basis Of Presentation	Basis of Presentation – The consolidated financial statements and accompanying notes have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position for the periods presented.
Risks And Uncertainties	Risks and Uncertainties - The Company has a limited operating history and has generated minimal revenues from its operations. The Company’s business and operations are sensitive to general business and economic conditions in the U.S. and worldwide. These conditions include short-term and long-term interest rates, inflation, fluctuations in debt and equity capital markets and the general condition of the U.S. and world economy. A host of factors beyond the Company’s control could cause fluctuations in these conditions, including the political environment and acts or threats of war or terrorism. Adverse developments in these general business and economic conditions, including through recession, downturn or otherwise, could have a material adverse effect on the Company’s financial condition and the results of its operations. The Company has only recently started to generate sales and we have limited marketing and/or distribution capabilities. The Company has limited experience in developing, training, or managing a sales force and will incur substantial additional expenses if it decides to market any of its current and future products and services with an internal sales organization. Developing a marketing and sales force is also time-consuming and could delay the launch of its future products and services. In addition, the Company will compete with many companies that currently have extensive and well-funded marketing and sales operations. The Company’s marketing and sales efforts may be unable to compete successfully against these companies. In addition, the Company has limited capital to devote to sales and marketing. The Company’s industry is characterized by rapid changes in technology and customer demands. As a result, the Company’s products and services may quickly become obsolete and unmarketable. The Company’s future success will depend on its ability to adapt to technological advances, anticipate customer demands, develop new products and services, and enhance the Company’s current products and services on a timely and cost-effective basis. Further, the Company’s products and services must remain competitive with those of other companies with substantially greater resources. The Company may experience technical or other difficulties that could delay or prevent the development, introduction or marketing of new products and services or enhanced versions of existing products and services. Also, the Company may not be able to adapt new or enhanced products and services to emerging industry standards, and the Company’s new products and services may not be favorably received. In addition, the Company may not have the capital resources to further the development of existing and/or new ones. On July 8, 2022, the Company received a letter from The Nasdaq Stock Market LLC advising us that we were not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of our common stock was below $1.00 per share for 30 consecutive business days. Pursuant to Nasdaq’s Listing Rules, the Company had a 180-day grace period, until January 4, 2023, during which the Company could have regained compliance if the bid price of our common stock closed at $1.00 per share or more for a minimum of ten consecutive business days. Subsequent to January 4, 2023, the Company has been granted an additional 180-day grace period. On June 12, 2023, the company effected a 10-to-1 reverse common stock split. Following the reverse stock split, the closing bid price of our common stock was above $1.00 per share for ten consecutive business days from June 12, 2020 to June 26, 2023. Pursuant to Nasdaq’s Listing Rules, the company was in compliance with Nasdaq Listing Rule 5550(a)(2). On June 27, 2023 the Company received written notice from the Nasdaq Stock Market notifying the Company that is had regained compliance with the minimum bid price requirement. Regarding the war between Russia and Ukraine, we have no direct exposure to those geographies. We cannot predict how global supply chain activities, or the economy at large may be impacted by a prolonged war in Ukraine or sanctions imposed in response to the war, or whether future conflicts, if any, may adversely affect our results of operations.
Revenue	*Revenue* - The Company recognizes revenues in accordance with Accounting Standards Codification (“ASC”) 606, “Revenue from contracts with customers”. Revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Deferred revenue represents amounts which still have yet to be earned. The Company generates revenue from the sale of disposable stem cell concentration kits. Revenues are recognized when control of the promised goods or services are transferred to the customer, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services, which is generally on delivery to the customer. Payments received for which the earnings process is not yet complete are deferred. As of June 30, 2023, the Company had $40,000 in deferred revenue. There was no deferred revenue as of June 30, 2022.
Concentration Risks	Concentration Risks – The Federal Deposit Insurance Corporation insures cash deposits in most general bank accounts for up to $250,000 per institution. The Company maintains its cash balances at four financial institutions. As of June 30, 2023, the Company’s balance exceeded the limit at two institutions.
Fair Value Of Financial Instruments	*Fair Value of Financial Instrument* – The Company’s financial instruments consist of cash and cash equivalents, and payables. The carrying amount of cash and cash equivalents and payables approximates fair value because of the short-term nature of these items. Fair value is an exit price, representing the amount that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. Fair value measurements are required to be disclosed by level within the following fair value hierarchy: Level 1 – Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 – Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 – Inputs lack observable market data to corroborate management’s estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. When determining fair value, whenever possible the Company uses observable market data, and relies on unobservable inputs only when observable market data is not available. As of June 30, 2023, and 2022, the Company had no outstanding derivative liabilities.
Basic and Diluted Income (Loss) Per Share	Basic and Diluted Income (Loss) Per Share – The Company follows Financial Accounting Standards Board (“FASB”) ASC 260 Earnings per Share to account for earnings per share. Basic earnings per share (“EPS”) calculations are determined by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding. During loss periods when common stock equivalents, if any, are anti-dilutive they are not considered in the computation. During the six-months ended June 30, 2023 and 2022, the Company had options to purchase 11,183 shares of common stock and warrants to purchase 2,284,932 shares of common stock; however, the effects were anti-dilutive due to the net loss. Following the approval of the Company’s Board of Directors, on June 12, 2023, the Company effected a 1-for-10 reverse split of the Company’s outstanding shares of common stock by filing a Certificate of Change Pursuant to NRS 78.209 with the Secretary of State of the State of Nevada. The filing of the Certificate of Change also reduced the authorized number of shares of the Company’s Common Stock from 50 million to five million. All share references in this filing have been restated to reflect the reverse split to the earliest period presented. No fractional shares were issued, and no cash or other consideration were paid in connection with the Reverse Stock Split. Instead, the Company issued one whole share of the post-Reverse Stock Split Common Stock to any stockholder who otherwise would have received a fractional share as a result of the Reverse Stock Split. As a result, the Company issued an additional 23,502 shares.
Cash Equivalents	*Cash Equivalents* – The Company classifies its highly liquid investments with maturities of three-months or less at the date of purchase as cash equivalents. Management determines the appropriate classification of its investments at the time of purchase and reevaluates the designations of each investment as of the balance sheet date for each reporting period. The Company classifies its investments as either short-term or long-term based on each instrument’s underlying contractual maturity date. Investments with maturities of less than 12 months are classified as short-term and those with maturities greater than 12 months are classified as long-term. The cost of investments sold is based upon the specific identification method.
Inventories	Inventories – Inventories are valued on a cost basis. The cost of inventories is determined on a first-in, first-out basis.
Recent Accounting Pronouncements	*Recent Accounting Pronouncements* – The Company has reviewed all recently issued, but not yet adopted, accounting standards in order to determine their effects, if any, on its results of operation, financial position or cash flows. Based on that review, the Company believes that none of these pronouncements will have a significant effect on its financial statements.

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2023	Jun. 30, 2022
FDIC insured amount	$ 250,000
Deferred revenue	$ 40,000	$ 0
Options [Member]
Reverse split description	1-for-10
Additional stock issued	23,502
Anti-dilutive Securities Excluded From Computation Of Earning Per Share	11,183	2,284,932
Stock description	50 million to five million

LICENSING AGREEMENTS (Details)	6 Months Ended
LICENSING AGREEMENTS (Details)	Jun. 30, 2023 USD ($)
Assets
Beginning Balance	$ 760,000
Amortization	0
Ending balance	760,000
Accumulated Amortization
Accumulated Amortization, Beginning Balance	(324,405)
Addition of new assets	0
Amortization	(46,042)
Accumulated Amortization, Ending Balance	$ (370,447)

LICENSING AGREEMENTS (Details Narrative) - USD ($)		1 Months Ended			3 Months Ended		6 Months Ended
LICENSING AGREEMENTS (Details Narrative) - USD ($)	Dec. 12, 2020	Feb. 28, 2022	Dec. 28, 2020	May 17, 2017	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2021	Jan. 31, 2021	Dec. 31, 2020	Feb. 02, 2016
License fees			$ 250,000
No of share Exchange												43,112
Restricted common stock												$ 100,000
obligation of the initial payment					$ 300,000		$ 300,000		$ 300,000	$ 300,000	$ 300,000
common stock Issue	$ 667								8,466	8,929	133,404
Company paid CMH					50,000		50,000		$ 40,000	$ 50,000	$ 50,000
License agreement description			(the “Upfront Royalty”), which can also be paid in CELZ stock at a discount of 25% of the closing price of $0.0037, which is based on the date of this agreement
Amortization expenses					23,021	$ 23,021	46,042	$ 46,042
Amortization expenses							22,970	22,970
Number of share issuance of common stock to Jadi Cell		18,018
Carrying value of patent					26,030		26,030
Expected amount of amortization							9,972
Payments upon completion of the IRB clinical trial				$ 200,000
Payments in the event of commercialization of technology				300,000
Option [Member]
Initial payment	$ 100,000			100,000
Payments upon signing agreement with university for the initiation of an IRB clinical trial				100,000
Payments upon filing an IND with the FDA				100,000
Payments upon dosing of the first patient in a Phase 1-2 clinical trial				200,000
Payments upon dosing of the first patient in Phase 3 clinical trial				$ 400,000
Percentage of discount on the basis of recent trading price				30.00%
Share price for two or more consecutive trading days				0.01
Option Warrant [Member]
Royalty payment percentage				5.00%
Non-royalty sublease income percentage				50.00%
License Agreement
Amortization expenses							586	586
Carrying value of patent					2,619		$ 2,619
Expiration period of finite-lived intangible assets							2026
Expected amount of amortization							$ 1,172
CMH [Member]
License fees							250,000
Expected annual amortization amount					46,000		46,000
StemSpine LLC [Member]
Amortization expenses							5,000	5,000
Carrying value of patent					40,000		$ 40,000
Expiration period of finite-lived intangible assets							May 19, 2027
Expected amount of amortization							$ 10,000
Jadi Cell [Member]
Amortization expenses							12,500	$ 12,500
Carrying value of patent					$ 187,500		187,500
Expected amount of amortization							$ 25,000

STOCKBASED COMPENSATION (Details)	6 Months Ended
STOCKBASED COMPENSATION (Details)	Jun. 30, 2023 $ / shares
Annual dividend yield	0.00%
Expected life (years)	5 years
Common stock price	$ 18.30
Option Warrant [Member]
Annual dividend yield	0.00%
Expected volatility	92.95%
Risk-free interest rate	0.81%
Expected life (years)	10 years
Common stock price	$ 16.90

STOCKBASED COMPENSATION (Details 1) - Option [Member]	6 Months Ended
STOCKBASED COMPENSATION (Details 1) - Option [Member]	Jun. 30, 2023 $ / shares shares
Stock option, Outstanding at the begining \| shares	11,183
Stock option, Outstanding at the end \| shares	11,183
Stock option, Vested \| shares	7,456
Weighted Average Exercise Price, Outstanding beginning \| $ / shares	$ 83.96
Weighted Average Exercise Price, Outstanding ending \| $ / shares	83.96
Weighted Average Exercise Price, Vested \| $ / shares	$ 117.47
Weighted Average Life Remaining, Outstanding beginning	9 years 1 month 9 days
Weighted Average Life Remaining, Outstanding ending	8 years 7 months 9 days
Weighted Average Life Remaining, Vested	8 years 7 months 13 days

STOCKBASED COMPENSATION (Details Narrative) - USD ($)	6 Months Ended
STOCKBASED COMPENSATION (Details Narrative) - USD ($)	Jun. 30, 2023	Sep. 06, 2021
Common stock price	$ 18.30
Employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	11,182
Common stock price	$ 16.90
Stock option, Issued	0
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	The options vested immediately as to 25% of the shares subject to the option, and will vest in three equal installments of 25% of the shares subject to the option on each of the next three annual anniversary dates of the grant date
Future estimated stock-based compensation	$ 58,455
Employee Stock Options [Member] \| Black Scholes Method [Member]
Options vested, value	$ 145,525
Board of Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		60,000

STOCKHOLDERS EQUITY (Details)	6 Months Ended
STOCKHOLDERS EQUITY (Details)	Jun. 30, 2023 $ / shares
STOCKHOLDERS EQUITY
Annual dividend yield	0.00%
Expected life (years)	5 years
Risk-free interest rate	0.81%
Expected volatility	92.95%
Common stock price	$ 18.30

STOCKHOLDERS EQUITY (Details 1) - Warrants [Member]	6 Months Ended
STOCKHOLDERS EQUITY (Details 1) - Warrants [Member]	Jun. 30, 2023 $ / shares shares
Warrants, Outstanding Beginning Balance \| shares	2,284,932
Warrants, Outstanding Ending Balance \| shares	2,284,932
Weighted Average Exercise Price, Outstanding beginning \| $ / shares	$ 26.59
Weighted Average Exercise Price, Outstanding ending \| $ / shares	$ 26.59
Weighted Average Life Remaining, Outstanding Beginning	4 years 2 months 19 days
Weighted Average Life Remaining, Outstanding Ending	3 years 8 months 19 days

STOCKHOLDERS EQUITY (Details Narrative) - USD ($)		1 Months Ended	6 Months Ended
STOCKHOLDERS EQUITY (Details Narrative) - USD ($)	May 03, 2022	May 31, 2022	Jun. 30, 2023	Mar. 31, 2022
Amendment description	pursuant to a Securities Purchase Agreement between the Company and the Purchasers dated as of April 28, 2022 (the “Purchase Agreement”), resulting in gross proceeds to the Company of approximately $17,000,000. The transaction was effected pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended and Rule 506(b) promulgated thereunder
Sale of shares of common stock	299,167
Pre-Funded Warrants Exercise price			$ 0.001
Purchase of warrants shares	456,389
Repurchase of common stock			2,000,000
Purchase of Pre-Funded Warrant and related Common Warrant	1,511,112
Common warrants exercise price			$ 20.00
Combined offering price of Pre-Funded Warrant and related Common Warrant	$ 22.50
Roth Capital Partners [Member]
Paid placement agent fee			$ 1,360,000
Issued warrant to purchase shares of common stock			113,334
Warrants [Member]
Warrants to purchase shares of common stock		1,624,446
Warrant exercise price		$ 20.00
Class of Warrant or Right, Outstanding			2,284,932	2,296,927
Private Offering [Member]
Warrants to purchase shares of common stock		456,389

SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative) - USD ($)		3 Months Ended		6 Months Ended
	Dec. 15, 2022	Jun. 30, 2023	Jun. 30, 2022	Jun. 30, 2023	Jun. 30, 2022
SIGNIFICANT RESEARCH AND DEVELOPMENT PURCHASES (Details Narrative)
Research and development expenses	$ 5,000,000	$ 309,480	$ 659,695	$ 628,509	$ 669,695
Initial payment amount	$ 2,000,000